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Na-NMR and metabolic studies of free radical injury in renal
hypoxia. M. Cross, P.A. Stewart-Richardson, G.J. Cowin, J. West-
huyzen, S.J. Fleming, and Z.H. Endre, University of Queensland
Departments of Medicine and Renal Medicine, Royal Brisbane Hospi-
tal, Herston, Australia. Oxygen-derived free radicals (OFR) are impli-
cated in ischemic acute renal failure (ARF). To assess this in the
isolated perfused rat kidney (IPRK) we used the hydroxyl radical
scavengers dimethylthiourea (DMTU) and dimethyl sulfoxide (DMSO)
during a 30 minute period of hypoxia and compared with controls:
changes in renal function, accumulation of renal Na measured by
23Na-NMR, adenine nucleotides, glutathione and lipid peroxide metab-
olite levels. Control kidneys were perfused for 90 minutes. High flow
hypoxia was induced at 60 minutes by switching to N2/C02 : 95%15%.
DMSO and DMTU, both 15 m, were added to the perfusate 15
minutes prior to the start of hypoxia. 23Na-NMR spectra were collected
throughout and averaged over 2 minute intervals. After 90 minutes
perfusion kidneys were freeze-clamped and assayed for metabolites.
Hypoxia caused a rapid decline in renal function, with reduced GFR,
and increased renal vascular resistance, FENa and FEK. Hypoxia of 30
minutes produced an immediate rise in intracellular Na to —130% of
baseline and marked decreases in ATP (0.89 0.25 vs. 0.19 0.14 mM,
SD, N = 6), total adenine nucleotide levels (1.44 0.23 vs. 0.68 0.34
mM, N = 5), energy charge (0.77 0.06 vs. 0.45 0.07, N = 5), and
reduced glutathione content (1.57 0.35 vs. 0.76 0.35 mM, N = 6).
In contrast, the levels of oxidized glutathione and lipid peroxide
metabolites were unchanged following hypoxia. Scavengers of OFR did
not prevent the decline in kidney function or alter the pattern of
metabolite changes. OFR scavengers significantly reduced the increase
in total renal sodium following hypoxia. This suggests a role for
OFR-injury during the induction of injury in this model, where high flow
persists with reduced Po2, providing a continuous source of oxygen for
OFR formation and illustrates the utility of 23Na NMR in the dynamic
monitoring of renal metabolic status in the intact kidney.
Low human kidney osmoprotectant levels are matched by low sodium
and urea levels. S. Chambers, P. Size/and, M. Lever, L. Bason, R.
Robson, Departments of Nephrology, Infectious Diseases and Bio-
chemistry, Christchurch Hospital, New Zealand. We have previously
shown the presence of osmotically active organic solutes or "osmopro-
tectants" in a variety of mammalian kidneys, including humans. The
levels in the human inner medulla were much lower than other
mammalian kidneys analyzed. In this study the osmoprotectants gly-
cine betaine (GB), myoinositol (MI), sorbitol (S) and glycerophospho-
choline (GPC) were measured and compared with sodium and urea in
human and rabbit inner medulla tissue samples. Concentrations
(mmol/kg tissue) are shown in the table (mean SEM).
Rabbits (N 8) Human (N = 11)
GB 64.3 (4.8) 2.7 (0.4)
MI 17.8 (1.3) 15.1 (1.3)
S 36.0 (6.8) 1.4(0.3)
GPC 10.5 (0.7) 3.2 (0.5)
Sodium 140 (4.8) 97 (3.5)
Urea 245 (18) 39 (4.7)
In humans the low concentrations of osmoprotectants were accompa-
nied by low sodium and urea concentrations. Significant correlations
were found within and across the species between urea and GPC (r =
0.74, P = 0.01), and urea and total methylamines (r = 0.95, P < 0.001).
This study confirms that the lower concentrations of osmoprotectants in
human kidneys are matched by low concentrations of urea and sodium
and provides evidence of a physiological relationship between the
osmoprotectants and other solutes.
Effect of angiotensin converting enzyme inhibitors on plasma erythro-
poietin concentration in healthy volunteers. M.C. Pratt, N.J. Lewis-
Barned, R.J. Walker, R.R. Bailey, B.I. Shand, J. Livesey, Department
of Medicine, Otago Medical School, Dunedin, Department of Nephrol-
ogy, Christchurch Hospital, Christchurch and Department of Endocri-
nology, The Princess Margaret Hospital, Christchurch, New Zealand.
Angiotensin II is necessary for erythropoietin (EPO) formation. Re-
cently it has been reported that angiotensin converting enzyme (ACE)
inhibitors may cause a significant lowering of the hemoglobin concen-
tration in patients with renal insufficiency. This is thought to be due to
the ACE inhibitor affecting EPO synthesis and'or release. This single
blind, cross-over study investigated the effect of low-dose captopril
and enalapril on plasma EPO concentration, hei oglobin concentration
and red blood cell count in 10 healthy volu.steers. After 28 days
treatment, there was a significant fall in mean plasma EPO concentra-
tion evident with both drugs (see Table). An insignificant, downward
trend in the hemoglobin concentration and red blood cell count was
found. EPO concentrations returned to baseline after stopping the ACE
inhibitor.
DayO Day28 P
EPO mU/mI Captopril
Enalapril
11.4 (1.2)
11.8 (0.9)
9.0 (1.4)
9.6 (0.8)
<0.05
<0.05
Hemoglobin giliter
Red blood cell count
Captopril
Enalapril
Captopril
140.8 (4.6)
142.6 (5.2)
4.98 (0.14)
138.1(6.0)
140.4 (4.8)
4.84 (0.16)
NS
NS
NS
10'2/liter
Enalapril 4.99 (0.12) 4.91 (0.14) NS
This study has shown that ACE inhibitors can significantly decrease
EPO synthesis and/or release, presumably by inhibition of angiotensin
II production. This could be important in patients with renal failure,
renal transplantation or other chronic conditions with an associated
anemia. Hematological parameters should be monitored in such pa-
tients when they are treated with an ACE inhibitor.
Effect of' neutral endopeptidase inhibition by oral SCH34826 in the rat
remnant kidney model. K. Jandeleit, M. Kanazawa, D. Casley, C.!.
Johnston, and B. Jackson, University of Melbourne Department of
Medicine, Austin Hospital, Heidelberg, Victoria, Australia. Progres-
sive renal failure is characterized by disturbed vasoactive peptide
status, including alterations in the renin-angiotensin and atrial natri-
uretic peptide (ANP) systems. We have studied the effects of
SCH34826, an inhibitor of neutral endopeptidase (EC 3.4.24.11), in the
rat remnant kidney model of renal failure. Renal neutral endopeptidase
is located principally in the renal tubular brush border where it acts to
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degrade ANP. Four weeks after l/8 subtotal nephrectomy SCH34826
was gavaged for three days (90 mg/kg twice daily) in adult rats (N = 7)
and changes compared with placebo (N = 5). Renal functional param-
eters, and systemic hemodynamic changes were assessed in awake rats.
Tissue neutral endopeptidase was assessed by radioligand binding in
tissue sections. Renal neutral endopeptidase was inhibited by 60%. This
was associated with a 230% rise in urinary ANP, a 56% rise in urinary
sodium and a 26% rise in urinary protein excretion (all P < 0.05). These
changes were not observed in the placebo group. Glomerular filtration
rate (mTcDTPA clearance), systemic blood pressure, plasma ANP
concentration, plasma and urinary cGMP and plasma renin and angio-
tensin II were not altered by treatment with SCH34826 or placebo.
These results suggest chronic administration of SCH34826 in estab-
lished renal failure inhibits renal neutral endopeptidase and has intra-
renal effects modulating natriuresis, without effects on systemic hemo-
dynamics or glomerular filtration rate.
The effect of felodipine on the proximal tubule. T.O. Morgan and D.
Thomas, Physiology Department, Melbourne University, Parkville,
Australia. Felodipine, a dihydropyridine slow calcium channel blocking
drug, produces a diuresis and natriuresis at doses that do not affect
blood pressure (BP), RBF, or GFR, suggesting direct decreases in renal
tubular reabsorption. We have used shrinking split-drop micropuncture
to determine the effect of felodipine on proximal tubular reabsorption.
Male Sprague-Dawley rats (250—300 g/body wt) were anesthetized with
mactin. The trachea, carotid artery, and jugular vein were cannulated
for infusion of saline at a rate of 2.34 mI/hr. The left kidney was
prepared for micropuncture. After two hours, mid-proximal fluid up-
take (Jv) was measured using shrinking split-drop micropuncture.
Intraluminal felodipine at a concentration of 50 g/ml decreased Jv by
24% (P < 0.05, paired t-test; N = 7). In a separate series of experi-
ments, BP and proximal tubular reabsorption were measured before
and 40 minutes after intravenous infusion of felodipine at a rate of 500
sg/kgJmin. BP decreased from 115 to 102 mm Hg (P < 0.001, paired
t-test; N = 6). Proximal tubular reabsorption decreased from a control
value of 2.57 0.2 to 2.26 0.2 x iO mm3mm2s (P <0.05, paired
t-test; N = 6). There was no change in the time in the control group.
Dibona has provided evidence for a direct effect of felodipine on the
distal tubule. The results of the present study demonstrate that felo-
dipine inhibits proximal as well as distal tubular reabsorption and may
thus inhibit transport all along the nephron.
Severe hyponatremia and atrial natriuretic peptide. Louise M. Burrell,
J.M. Palmer and P.H. Baylis, Department of Medicine, University of
Newcastle upon Tyne, United Kingdom, introduced by C.!. Johnston,
Department of Medicine, Austin Hospital, Heidelberg, Victoria, Aus-
tralia. The pathogenesis of hyponatremia (HX) remains debated, and to
date few studies have investigated the possible role of atrial natriuretic
peptide (ANP) in this disorder. Patients with severe HX (plasma sodium
<125 mmol/liter, N = 45), and age, sex and condition matched
normonatremic controls (NX, N = 45) were studied prospectively.
Patients were classified according to clinical assessment of extracellular
fluid volume as hypervolemic, normovolemic or hypovolemic. Samples
were obtained after an overnight fast for the measurement of plasma
sodium (pNa), plasma osmolality (pOsm), plasma ANP (pANP), plasma
vasopressin (pVp), renin and aldosterone. Results are expressed as
mean SCM, and compared using unpaired t-test.
Hypervolemia HX (N = 20) NX (N = 20) P
pNa mmol/liter 118 1.4 137 1.1 <0.001
pANPpmol/liter 67.5 19.5 45.1 8.6 NS
pVp pmol/liter 2.9 0.5 2.2 0.5 NS
Normovolemia HX (N = 25) NX (N = 25) P
pNa mmol/liter 121 1.1 138 0.4 <0.001
pANPpmol/liter 17.8 2.7 5.6 1.0 <0.001
pVppmol/liter 2.8 0.9 0.6 0.1 <0.01
All patients with hyponatremia had detectable or elevated plasma
vasopressin despite hypoosmolality. Plasma ANP concentrations were
significantly elevated in patients with normovolemic hyponatremia, but
not in those with hypervolemic hyponatremia. The mechanisms under-
lying the secretion of both vasopressin and ANP in normovolemic
hyponatremia are unclear. This work was supported by the MRC,
United Kingdom.
Machine learning applied to the diagnosis of giomerular disease.
J. W.M. Agar and G.!. Webb, Department of Medicine, Geelong
Hospital, and Department of Computing and Mathematics, Deakin
University, Geelong, Victoria, Australia. Though renal biopsy is un-
challenged as the diagnostic gold-standard for most renal diseases, in
circumstances where biopsy is contraindicated or delayed, suitably
reliable non-invasive techniques would be of significant clinical benefit.
Applying machine learning strategies, we have developed expert sys-
tems (ES) which, in turn, have induced diagnostic criteria from a
database of 284 consecutive biopsies (31 separate diagnoses), each
comprising 38 clinical variables. Two different types of ES were
developed. The first analyzed which of 31 diagnoses was present for
each individual case while the second analyzed a case and determined
whether or not one particular diagnosis was present. Eighty percent of
cases were randomly selected to "train" the ES to develop diagnostic
rules, which were then applied to the remaining 20% of cases. One
hundred of each type of ES were developed, each time using a different
random selection of training cases. On average, the first type of ES
correctly diagnosed 53.69% cases compared to 3% expected random
diagnosis and 48.31% for 4 expert clinicians given the same data. As
22/31 diagnoses comprised <10 cases each and thus limited the diag-
nostic accuracy, these results are highly significant. If the ES examined
single conditions and was applied only where >15 cases of each
diagnosis were present, the total accuracy of diagnosis was: micro-
scopic polyarteritis 95.37%, minimal lesion nephrotic syndrome
96.50%, IgA nephropathy 81.26%, lupus nephritis 96.27%, focal gb-
merulosclerosis 92.06%, membranous nephropathy 92.56%, mesangial
(non-IgA) proliferative GN 92.56%. We believe this pilot project has
great promise, particularly with database expansion, and conclude
machine learning may provide a useful diagnostic adjunct to renal
biopsy in glomerular disease.
Prognosis for spinal cord injury and disease in end.stage renal failure—
Australia, 1970—1991. G.M. Patrick, J.F. Mahony, A.P.S. Disney,
Department of Renal Medicine, Royal North Shore Hospital, Sydney,
2065 and ANZDATA Registry, Australia. A survey of participating
renal units for patients with spinal cord injury and disease was con-
ducted by questionnaire in 1988 and 1990. Information regarding
treatment and outcome was obtained from the ANZDATA Registry
with the units' consent. Twenty-two paraplegic patients (19M and 3F)
and 2 quadriplegic patients (2M) were identified in the period 1970—1991
(group A: mean age 38, range 12—65, years); 25 patients with spina bifida
(19M and 6F) were identified in the same period (Group B: mean age28,
range 18—48, years). Initial treatments in Group A and Group B,
respectively were: hospital HD (54% and 84%), hospital PD (25% and
8%), hospital/satellite PD (21% and 4%). The major treatments within
the study period (Group A: 1631 months; Group B: 1949 months) were
hospital HD (37.7% and 26.6% respectively), satellite HD (1.5% and
9.0%), home HD (33.8% and 30.5%), CAPD (7.5% and 1.3%) and
transplantation (16.0% and 32.4%). Transplantation was performed in 8
patients in Group A (1 living-related and 8 cadaveric grafts) and in 13
patients in Group B (2 living-related and 11 cadaveric grafts). One
paraplegic patient received 2 cadaveric transplants. Rehabilitation and
quality of life data, to the time of death or the last return, were jointly
assessed from the Registry on a scale of 2 to 7, a higher score being
associated with a greater degree of disability. Of all patients in Group A
16.6% had a score of 2 (cf. 72% in Group B) and 29% a score of 7 (cf.
0% in Group B). Cumulative survival for Groups A and B at 1, Sand 10
years was 91.5% vs. 100%, 71.3% vs. 100%, and 53.2% vs. 84.6%,
respectively. Causes of death included myocardial infarction, sepsis,
and dialysis dementia. In the paraplegic group 2 patients withdrew from
treatment. The prognosis for patients with spinal cord injury and
disease and end-stage renal failure is good in the long-term.
Uremic skeletal muscle metabolism: The effect of erythropoietin (EPO).
C.H. Thompson, D.J. Taylor, G.J. Kemp, J.G.G. Ledingham, B.
Rajagopalan, G.K. Radda, MRC Biochemical and Clinical Magnetic
Resonance Unit, John Radcliffe Hospital, Oxford, United Kingdom.
Fatigue and lethargy are common in end-stage renal failure and have
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been attributed to both anemia and intrinsic metabolic myopathy. To
distinguish these, we studied patients on hemodialysis before (N = 7)
and after (N = 4) the hemoglobin (Hb, g/dl) rose with EPO therapy.
Using 31P magnetic resonance spectroscopy, we studied forearm mus-
cle at rest, during 12 minutes aerobic exercise and in recovery. This
allowed calculation of muscle phosphate (as Pi/ATP) at rest, the rates of
phosphocreatine (Per) depletion (Q, m/min) and estimated lactic acid
production (L, mM/mm) on starting exercise, the end-exercise (ADP)
(MM) (the drive for ATP production) and, after exercise, the initial rate
of Cr recovery (R, mM/mm, a measure of mitochondrial ATP synthe-
sis).
Hb
Rest
Pi/ATP
Exercise Recovery
RL Q Duration (ADP)
Control 13.5 0.32 1.3 8 12 30 21
Uremic 8.0 Q45 ioa 22 6 70 18
OnEPO 115b 0,44a 34b 9b 5a 23b 3a
P < 0.05; cf control patients, 'cf uremic patients pre-EPO
The rapid acidification and 1Cr depletion upon exercise, with near-
normal PCr recovery on account of high ADP, all suggest partially-
compensated mitochondrial dysfunction. Almost all these were normal-
ized by EPO, suggesting that reduced mitochondrial 02 delivery
contributes to uremic myopathy. Exercise duration did not improve,
implying some residual metabolic dysfunction. This may be related to
the incomplete restoration of Hb or, more likely, to an abnormality of
uremic cell metabolism related to ion transport or elevated Pi/ATP
persisting after EPO.
Randomized controlled trial of cyclophosphamide (C), warfarin (W)
and dipyridamole (D) in idiopathic membranous glomerulonephritis
(MGN). B.F. Murphy, I. McDonald, K.F. Fairley, P.S. Kincaid-Smith,
Departments of Nephrology, St. Vincent's Hospital, Fitzroy, and The
Royal Melbourne Hospital, Australia. A previous trial of C, W, and D
in MGN demonstrated marked reduction in proteinuria following 3
years therapy.' C rarely causes sterility if used for 6 months.2 Accord-
ingly, we performed a trial where the treatment consisted of 6 months
C and two years W and D. Forty patients with idiopathic MGN were
randomized to receive either no treatment or this regime. A significantly
greater (P < 0.05) reduction in urine protein excretion was seen at 6, 12,
18 and 24 months in the treatment group. Plasma albumin was also
significantly higher in the treatment group at 18 and 24 months (P <
0.05). There was no significant deterioration in renal function in either
group during the two years of the trial. As progressive deterioration in
renal function in MON is associated with persistent heavy proteinuria
and does not occur in the absence of the nephrotic syndrome,3 these
results suggest a beneficial effect of treatment. Such benefit would be
expected to result in better preservation of renal function over longer
term follow-up.
Lymphokine production by glomerular T cells in anti-GBM glomeru-
Ionephritis In mice. P.G. Tipping, J. Demelis and S.R. Holdsworth,
Monash University Department of Medicine, Monash Medical Centre,
Clayton, Australia. T cell participation has been demonstrated in
proliferative glomerulonephritis (GN) in a number of species including
humans, rats and rabbits. The functional role of T cells in GN is
unknown. In order to study lymphokine production by T cells, a murine
model of anti-GBM GN was developed. GN was initiated in mice
presensitized to sheep globulin, by an intravenous dose of sheep
anti-murine GBM globulin. This reliably produced proteinuria (day 5,
2.87 0.59 mg/18 hr, normal 1.02 0.27 mg/l8 hr) and a proliferative
GN with prominent glomerular macrophage infiltration. A significant
infiltrate of CD3 and CD4 positive T cells was present in glomeruli from
day 1 (CD3 positive T cells 2.9 0.8 cells/glomerular cross section
(c/gcs), normal 0.3 0.2 c/gcs). Lymphokine production by isolated
glomeruli in culture was assessed using specific sensitive ELISA's for
interleukin 4 (IL-4) and interferon (IFN7), IL-4 production was signif-
icantly increased on day 1 (33 9 pg/b3 gloms/24 hr) and day 3 (63
16 pg/lU3 gloms/24 hr compared to normal (9 9 pg/lU3 gloml24 hr).
IL-4 production was not increased on day 5. In contrast IFN7 produc-
tion was detectable only on day 5 (275 176 pg/lU3 glom/24 hr). These
studies provide evidence for a functional role of T cells in ON via
lymphokine production and demonstrate a reciprocal relationship be-
tween IL-4 and IFN production by glomerular T cells.
Heavy and light chain variable regions of a lymphocytotoxic human
monoclonal autoantibody are encoded within the germ line. D.A. Power,
C. Cunningham, B.K. Weber, 1. Al Muzairai, P. Grabowski, Depart-
ments of Nephrology and Clinical Immunology, St. Vincent's Hospital,
Fitzroy, Australia. Sera from patients undergoing dialysis commonly
contain 1gM autoantibodies directed to surface antigens on lympho-
cytes. Apart from causing confusion in interpretation of the cross match
test, they appear to have little function, although they do seem to occur
following viral infections. In a search for human antibodies directed to
HLA antigens, we have transformed B lymphocytes from a highly-
sensitized dialysis patient using Epstein-Barr virus and subsequently
fused transformed lymphocytes secreting cytotoxic antibodies with the
mouse-human heteromyeloma SBC-H20. One of the lines obtained,
FWE, secretes an IgMK autoantibody which lyses T and B lymphocytes
from the original cell donor and all normal individuals as well as a
variety of hematopoietic cell lines. This antibody could be removed by
absorption with fetal but not adult erythrocytes, suggesting that it was
directed to the fetal blood group antigen i. The variable regions of this
antibody were then sequenced using cDNA obtained by reverse tran-
scription of total cellular RNA. The variable regions were amplified by
PCR using specific primers and cloned into Ml3mpl8. The V region
genes of both heavy and light chains and the JH chain were found to be
encoded by known germ-line sequences (that is, unmodified gene
sequences in genomic DNA). For the heavy chain these were members
of the VHIV and H5 families, respectively; both families are known to
be used frequently in early life when the repertoire of the immune
response is being formed. These data suggest that autoantibodies in sera
from potential transplant recipients are a normal part of the antibody
repertoire whose synthesis is increased at certain times by viral
infection.
The influence of TGF-13, on fibronectin synthesis and IHCS splice
patterns in cultured human mesangial cells. N.G. McKay, N.E. Haites,
D.A. Power, Departments of Nephrology and Clinical Immunology, St.
Vincent's Hospital, Fitzroy, Victoria, Australia. Fibronectin is one of
the glycoproteins which accumulates within the mesangium in IgA
nephropathy. Since there is evidence that transforming growth factor /3
(TGF-/3) is involved in the pathogenesis of experimental mesangial
proliferative glomerulonephritis, we have determined the effect of
TGF-/31 on fibronectin synthesis by cultured human mesangial cells. In
both cycling and growth-arrested mesangial cells, fibronectin mRNA
detected by Northern blots increased in cells stimulated with TGF-13,
relative to controls over a 24 hour period. Study of fibronectin secretion
into the extracellular matrix (ECM) and culture supernatant by ELISA,
Western blotting and 35S-methionine labeling showed that fibronectin
synthesis was increased, but that all of the increase was deposited
within the deoxycholate-insoluble ECM. One potential explanation for
this pattern was considered to be an alteration in the mRNA splice
pattern of the IIICS region of fibronectin which contains two cell-
binding domains. Oligonucleotide primers were constructed, therefore,
flanking the IHCS region of the fibronectin gene and mesangial cell
cDNA amplified by polymerase chain reaction. Four products (VO,
V64, V89 and V120) were obtained corresponding to 4/5 splice variants
known to occur in this region. The dominant species was VO, where the
whole IIICS region is excised. There was, however, no alteration in the
cells stimulated with TOF-J3, so the explanation for preferential incor-
poration of fibronectin into the extracellular matrix following stimula-
tion of mesangial cells with TGF-j3, remains obscure.
'Proc 2nd Asian Pacific Cong Nephrol 164—172, 1983
2 Lancet i:568—569, 1972
Clinical Nephrol 30:175—181, 1988
C4 null phenotype: A simple method for distinguishing point mutations
from gene deletions. J.F. Knight, G. Fanning, M.C. Falk, L.P. Roy,
Renal Research Laboratories, The Children's Hospital Camperdown,
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NSW, Australia, Both homozygous and heterozygous C4 null pheno-
type have been associated with an increased risk of autoimmune
disease. There has been controversy as to whether reduced levels of
plasma C4 contribute directly to disease pathogenesis or whether the
association reflects linkage with other genes in the major histocompat-
ibility complex (MHC). The null phenotypes identifiable by electropho-
resis and immunostaining of plasma correspond to a variety of abnor-
malities at the DNA level. Some C4 null individuals have deletions of
the entire C4A or C4B genes, while others have an intact gene which is
not expressed (presumably a point mutation). We have used the
polymerase chain reaction (PCR) to amplify a 550 bp fragment of the
genes for C4. The primers used hybridize with both the C4A and the
C4B genes, and span the region coding for amino acids 1091—1206,
which includes the isotypic residues which differentiate C4A from C4B.
Digestion of the PCR product with the restriction enzyme NIa IV
produces two bands of 325 and 290 bp. Our studies of C4 null phenotype
in IgA nephropathy have led to the identification of 67 individuals with
C4 null phenotype, of whom 33 have IgA nephropathy. We have
submitted DNA collected from these individuals to this PCR analysis.
The 290 bp band was absent in I of 7 individuals with homozygous C4A
null phenotype and reduced to 50% intensity in another 3 of the 7. The
290 bp band was also reduced in intensity in 17/32 with C4A heterozy-
gous null phenotype. The 325 bp band was absent in 9/11 individuals
with homozyogus C4B null phenotype and reduced in intensity in 2/17
individuals with C4B heterozyogous null phenotype. The bands were
both present at full intensity in another 78 individuals who did not show
any C4 null phenotype at the protein level. These results suggest that
the 290 bp band corresponds to the C4A gene, and the 325 bp band
corresponds to the C4B gene. Absence or reduced intensity of a band
suggests that the C4 null phenotype is due to a homozygous or
heterozygous gene deletion, respectively. In those individuals with null
protein phenotype but a normal PCR study failure of gene expression is
probably due to point mutation. This method will be useful in deter-
mining whether the associations between autoimmune disease and C4
null phenotype are due to gene deletions, or point mlitations, or both;
the latter would imply that the association was due to the reduced level
of plasma C4 rather than to linkage disequilibrium with other genes in
the MHC.
Transforming growth factor-fl (TGFI3) production by rat mesangial
cells. D.J. Nikolic-Paterson, H.C. Ramm, Y. Yu, and R.C. Atkins,
Department of Nephrology, Monash Medical Center, Clayton, Victo-
ria, Australia. TGFP is a multifunctional cytokine which has both
anti-inflammatory and prosclerosing activities. Cultured glomerular
mesangial cells have been shown to respond to exogenous TGF/3 by
decreased proliferation and increased synthesis of extracellular matrix
components. Also, glomerular TGF/3 production has been shown to be
involved in experimental glomerulosclerosis. In this study, the potential
of mesangial cells to make TGF/3 was examined. Northern blot analysis
of total cellular RNA using a rat TGFf3I cDNA probe revealed
expression of a single 2.5 kb mRNA species by a cloned rat mesangial
cell line (1097). TGF/31 expression was observed under conditions of
serum-starvation (0.5% FCS for 3 days), rapid growth and confluency.
TGF/3 protein production by rat mesangial cells cultured on glass slides
was detected with a rabbit anti-porcine TGFj3 polyclonal antibody.
Similarly, TGFJ3I gene expression was detected in a cloned mouse
mesangial cell line (B2A2) under conditions of serum-starvation, rapid
growth and confluency, and antibody labeling of cells cultured on glass
slides confirmed the production of TGF/3 protein. A faint TGFI3I
mRNA band could be detected with 20 jg of total cellular RNA from
normal rat kidney. This gene expression was found primarily in the
medulla and glomeruli. To assess the effects of proinflammatory stimuli
on TGF3 production by resident glomerular cells, glomeruli from
normal animals were cultured for 6 or 24 hours with IL-I a or LPS +
PMA. Under these conditions, levels of TGF/31 gene expression were
equivalent or increased compared to freshly isolated glomeruli. In
summary, cloned rat and mouse mesangial cells have been shown to
constitutively express the TGFj31 gene and to make the protein prod-
uct. The demonstration of TGF/31 gene expression in normal rat
glomeruli and its maintenance under conditions of inflammatory stimuli
indicates that this cytokine is likely to be involved in regulation of both
normal glomerular function and its' response to inflammatory injury.
Prevention of glomerular injury, cytokine production and mononuclear
and endothelial activation in nephrotoxic nephritis (NTN) by therapy with
CD4 monoclonal antibody. A. Tsuchida, J. Maguire, M. Sayegh, E.
Milford, H.H. Salem, and W.W. Hancock, Departments of Pathology,
Immunology and Medicine, Monash Medical School, Melbourne, Vic-
toria, Australia and Immunogenetics and Transplantation, Harvard
Medical School, Boston, Massachusetts, USA. CD4+ T cells are
instrumental to virtually all immune responses but their role, and that of
cellular immunity in general, in the immunopathogenesis of glomerular
injury is unknown. We studied the effects of CD4 mAb therapy in a rat
model of accelerated NTN. Sprague-Dawley rats were preimmunized
with normal rabbit serum and injected 5 days later with rabbit anti-rat
NTN serum. Rats were treated with CD4 mAb (BWH 4,500 g/kgIday,
i.p.) for the 5 days pre-NTN or for 10 days post-NTN injection. Effects
of CD4 mAb were evaluated by serial examination of renal function (Cr,
proteinuria), histology, blood levels of TNF, IL-6, protein C (PC) free
protein S (FPS), and immunoperoxidase for leukocytes, cytokines
(IL- 1, IL-2, IL-6, TNF, IFN-g) and activation markers (IL-2R, PCNA,
thrombomodulin, ELAM-1 and ICAM-1). During the first 24 hours
post-NTN, glomeruli in untreated rats showed infiltration by neutro-
phils, macrophages and T cells, in conjunction with upregulation of
ELAM-l, ICAM-l and Class II expression, fibrin deposition and
downregulation of thrombomodulin. Glomeruli were also densely
stained for IL-i, IL-2, IL-6 and TNF. Proliferation of glomerular cells
occurred thereafter. Pretreatment with CD4 mAb decreased or abro-
gated many of these events; results at 2 weeks post-NTN injection
were:
Cr
mg/dl
Proteinuria
mg/day
Macrophages/
glomerular XS
Normal rats 1.5
No Rx NTN 2.3
Rx 5 days pre-NTN 1.2
Rx 10 days post-NTN 2.1
0.4
0.2
0.3
0.6
470 69
1262 105
686 224
484 162
1.5 0.7
6.5 0.2
2.9 0.9
6.5 0.1
TNF IL-6
pg/ml U/mI
PC FPS
%
2±4 2±1
117±41 19±13
10±10 6±2
77±49 15±6
100±10
66±15
77±32
77±4
93±9
46±3
62±10
88±6
In summary, development of NTN was associated with a mononuclear
cell infiltrate and local production of the cytokines IL-I, TNF and IL-6,
which in vitro are known to be mitogenic for mesangial cells. CD4 mAb
maintained renal function, blocked development of proliferative GN,
and prevented local cell activation and cytokine production, but only if
therapy was begun pre-NTN injection; therapy post-NTN suppressed
proteinuria but was otherwise ineffective. We conclude that: (1) CD4
mAb can be used to prevent but not reverse the cytokine production,
intraglomerular coagulation and deterioration in renal function charac-
teristic of nephrotoxic nephritis, and (2) such data provide important
evidence for a pathogenic role for CD4+ cells in this model.
Suppression of rat nephrotoxic nephritis (NTN) by treatment with
anti-IL-2R (CD25) monoclonal antibody (mAb) W.W. Hancock, A.
Tsuchida, J. Maguire, H.H. Salem, and J.W. Kupiec-Weglinski, De-
partments of Pathology, Immunology and Medicine, Monash Medical
School, Melbourne Victoria, Australia, and Surgical Research Labo-
ratory, Harvard Medical School, Boston, Massachusetts, USA. CD25
mAb therapy has proven effective in clinical and experimental immu-
nosuppression of allograft rejection and several autoimmune diseases.
Given the increasing evidence for a role for IL-2R+ mononuclear cells
(MNC) in the pathogenesis of renal dysfunction in various forms of
glomerulonephritis and other renal diseases, we studied the effects of
CD25 mAb therapy on development of a rat model of accelerated NTN.
Sprague-Dawley rats were pre-immunized with normal rabbit serum
and injected 5 days later with rabbit anti-rat NTN. Rats were treated
with CD25 mAb (ART-18, 300 gIkg/day, i.p.) for the 5 days pre-NTN
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or for 10 days post-NTN injection. Effects of CD25 mAb were evalu-
ated by serial studies of renal function (Cr, proteinuria); circulating
levels of TNF, IL-6, protein C (PC) and free protein S (FPS); histology
and immunohistology using mAbs to leukocytes, cytokines (IL-i, IL-2,
IL-6, TNF, IFN-g) and activation antigens (IL-2R, PCNA, thrombo-
modulin, ELAM-1 and ICAM-l). CD25 mAb given either prior to, or
following, injection of NTN serum was effective at suppressing devel-
opment of glomerular injury and deterioration of renal function, al-
though pre-treatment was superior to therapy begun post-NTN. Results
of tests of renal function (creatinine, urinary protein), cytokine produc-
tion, circulating levels of anti-coagulant proteins and leukocyte infiltra-
tion at 2 weeks post-NTN injection were:
Cr
mg/dl
Proteinuria
mg/day
Macrophages!
glomerular XS
Normal rats
No Rx NTN
Rx 5 days pre-NTN
Rx 10 days post-NTN
1.5 0.4
2.3 0.2
1.4 0.3
1.3 0.1
470 69
1262 43
688 231
984 32
1.5 0.7
6.5 0.2
2.1 1.3
4.3 0.1
TNF
pg/mi
IL-6
U/mi
PC FPS
%
2±4
117±64
15±3
116±41
2±1
19±13
7±2
9±5
100±10
66±15
77±33
90±13
93±9
46±3
78±4
72±12
In summary, CD25 mAb therapy decreased glomerular MNC infiltra-
tion, local production of the mesangial mitogens IL-i, TNF and IL-6,
and markedly diminished glomerular injury and proliferation. These
data indicate an hitherto unsuspected role for IL-2R+ cells in this
model, and suggest that CD25 mAb therapy may prove of clinical
relevance to therapy during the acute phase of some forms of prolifer-
ative glomerulonephritis.
Respiratory burst cytochrome b558 and reactive oxygen species (ROS)
in proteinuric passive Ileymann's nephritis. T.J. Neale, R. Ulirich, P.P.
Ojha, H. Poczewski, A.J. Verhoeven, and D. Kerjaschki, Department
of Medicine, Wellington School of Medicine, Institute of Pathology,
Vienna, Austria, and Central Laboratory of The Netherlands Red
Cross Transfusion Service. Passive Heymann's nephritis (PHN), a
complement-dependent rat model of human membranous nephropathy,
is initiated by antibody with specificity for glomerular epithelial cell
(GEC) membrane antigens. Although PHN is independent of inflamma-
tory/phagocytic cells, ROS have been implicated in its pathogenesis.
We used monoclonal antibodies with specificity for the two subunits of
cytochrome b558, an essential component of the oxidoreductase re-
sponsible for the respiratory burst, to determine if glomeruli possess
this capability. Both subunits were localized within visceral GEC by
indirect IF in a punctate granular pattern. Immunogold EM revealed the
cytochrome was restricted to GEC vesicles, the basal GEC cell
membrane and vesicular extracellular structures adjacent to immune
deposits. Immunoblotting detected the cytochrome in high concentra-
tions in lysates of glomeruli isolated from proteinuric PHN rats, but in
trace amounts, only in controls. Depletion of complement with cobra
venom factor abolished the expression of the cytoehrome implying
biosynthetic dependence. As evidence of cytochronie functional activ-
ity, H202 was localized in proteinuric PHN glomerular capillary walls
using a novel ex vivo cerium chloride perfusion EM histochemical
technique. We conclude that the GEC has the enzymatic machinery to
mount the respiratory burst, that this is amplified in proteinuric PHN
and that ROS (H202) generated by the respiratory burst may have a
causal role in the alteration of glomerulai- permselectivity in this model.
The effect of different antihypertensive agents on mesangial function
following partial renal ablation. J. Odum, J. Purkiss, P.F. Naish, School
of Postgraduate Medicine, Keele University, Stoke-on-Trent, United
Kingdom. Differing classes of antihypertensive agents have different
efficacy in preventing proteinuria and glomerulosclerosis (GS) in the rat
remnant kidney model despite comparable reductions in systolic blood
pressure (SBP). Reasons for this phenomenon are unclear. Increases in
mesangial trafficking of macromolecules (MM) is proposed as one
mediator of OS in this model. We studied mesangial kinetics in Wistar
rats following either sham operation (2K) or I and 1/3 nephrectomy
(4/3Nx) in untreated rats, and compared kinetics with rats treated with
enalapril (EN) or the triple drug regimen of hydrallazine, hydrochlor-
thiazide and reserpine (HHR). EN prevents proteinuria and GS in this
model whereas HHR does not. SBP elevation following 4/Nx was
prevented by both EN and HHR. At 4 weeks post- 4/3Nx or 2K, rats
underwent arterial injection with iodinated aggregated BSA (I-aggBSA)
at a dose of 30 mg/100 g body weight. Groups of rats (5 at each time
point) were sacrificed at 2, 4 and 8 hours post-injection and concentra-
tion of I-aggBSA in blood, heart, liver, spleen and isolated glomeruli
quantified. At each time point there were no differences between any
group of rats in concentration of I-aggBSA in blood, heart, liver or
spleen. Mesangial kinetics were identical in 2K rats treated or un-
treated. Kinetics in 4/3Nx rats are shown below (mean SEM). Uptake
of I-aggBSA is expressed as pg/mg glomeruli.
2 Hours 4 Hours 8 Hours
2K
4/3Nx
4/3Nx EN
4/3NxHHR
0.714 0.08
0.766 0.13
0.785 0.11
1.159 0.24
0.738 0.08
1.336 0.24a
1.006 0.07
0.959 0.42
0.462 0.03
0.519 0.12
0.932 0.l3l
0.865 0.25
a p = 0.001; b P = 0.002; P = 0.0001; all vs. 2K
These results confirm that increases in mesangial uptake and clearance
of MM occur in remnant glomeruli. Trafficking is reduced by EN
treatment by mechanisms affecting clearance of MM from the mesan-
gium. Increases in trafficking were maintained by HHR, a therapy
associated with progressive GS.
Deoxyspergualin treatment prevents renal function impairment in
experimental anti-GBM glomerulonephritis (GN). H. I'. Lan, D.J. Ni-
kolic-Paterson, M. Zarama-Medina, P.G. Kerr, R.C. Atkins, Depart-
ment of Nephrology, Monash Medical Centre, Clayton, Victoria,
Australia. Deoxyspergualin (DOSP), a new immunosuppressant drug,
has been reported to modify the course of spontaneous lupus-like
glomerular lesions in susceptible mice. We have investigated the effects
of DOSP-treatment in accelerated anti-GBM GN in the rat. Treatment
consisted of daily intraperitoneal injection of DOSP (5 mg/kg body wt)
or vehicle alone from day 0 until sacrifice. Groups of 5 animals were
sacrificed at days 7, 14, and 21. Macroscopically, untreated animals
developed large white kidneys, whereas kidneys from DOSP-treated
animals maintained a normal appearance and weight (P < 0.001).
Results for hematuria (HU), proteinuria (PU) and creatinine clearance
(Ccr) are shown below. Untreated animals developed severe hematuria,
severe proteinuria, and exhibited a significant decrease in C. at days 14
and 21. DOSP-treatment produced complete suppression of haema-
tuna, and maintained normal renal function as assessed by Car.
However, DOSP-treatment had only a limited effect upon proteinuria,
with only the day 14 group demonstrating a significant decrease. In
conclusion, DOSP-treatment improved renal function and reduced
renal damage in accelerated anti-GBM GN. Thus, DOSP may be a
potential new drug for the treatment of human GN.
HU 0-4+ PU mg/24 hours Ccr mi/mm
untreat treat untreat treat untreat treat
Day 7 + (2) 0 (5) 262 55 297 60 1.4 0.1 1.4 0.2
++ (3)
Day 14 ++ (2) 0 (5) 445 59 228 65 0.9 0.1 1.4 0jb
+++ (3)
Day 21 +++ (5) 0(5) 452 82 336 120 0.6 0.1 1.4
a p < 0.05, b P < 0.001, compared to untreated group
Glomerular fibrinolytic activity (GFA) in anti-GBM induced glomeru-
Ionephritis (GN) in rabbits. J. Malliaros, P.G. Tipping, J. Wojta, and
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S.R. Holdsworth, Monash University Department of Medicine, Mo-
nash Medical Centre, Clayton, and Department of Diagnostic Haema-
tology, Royal Melbourne Hospital, Parkville, Australia. Fibrin is an
important mediator of injury in GN. Glomerular fibrin deposition
(GFD), is dependent on macrophage infiltration and is associated with
augmented glomerular procoagulant activity. The contribution of GFA
to GFD in GN is unknown. Changes in GFA were studied in GN with
marked GFD and prominent macrophage infiltration (autologous phase
anti-GBM GN) and contrasted with GN without GFD or macrophage
infiltration (heterologous phase anti-GBM GN) in rabbits. Total GFA
was measured by a solid phase plasminogen-dependent 1251 fibrin lysis
assay. GFA was significantly reduced in autologous GN (1.27 0.88 ng
fibrin lysed per l0 glom/2 hr), compared to normal glomeruli (57.1
27.8 ng/103 gloml2 hr; P < 0.05). GFA was augmented during heterol-
ogous GN (174 64 ng/103 glom/2 hr). Fibrin autography revealed both
tissue plasminogen activator (tPA) and urokinase (uPA) activity in
normal glomeruli. Both tPA and uPA were decreased in autologous GN
but not in heterologous GN. Reverse fibrin autography revealed in-
creased plasminogen activator inhibitor type 1 (PAl-I) activity in
autologous GN compared to normal glomeruli and heterologous GN.
PAl- I production measured by ELISA was significantly increased in
autologous GN (0.10 0.03 ng/103 glomI24 hr) compared to normal
glomeruli (0.02 0.01 ng/l03 glomI24 hr; P < 0.05). PAI-l was
undetectable in heterologous GN. These results demonstrate that fibrin
deposition in GN is associated with decreased GFA due to decreased
production of tPA and uPA and increased production of PAI-l. These
changes favor fibrin accumulation in GN.
Compensatory renal hypertrophy (CI4H); Cell growth and transport
studied in primary proximal tubular cell culture (PPTCC). C.A. Pollock
and M.J. Field, Department of Medicine, University of Sydney, Con-
cord Hospital, NSW, Australia. Significant alterations in the tubular
handling of Na are observed in vivo in CRH. In order to determine
whether altered growth and transport characteristics persist in vitro, we
measured these properties in confluent PPTCC derived from normal
animals (N), and those with CRH induced by nephrectomy performed 4
to 6 weeks earlier. Enhanced growth potential was retained in the CRH
cells compared with N cells, as evidenced by an increased cellular
protein content (250 12 vs. 151 II pg protein/cell; P < 0.001), and
a somewhat lesser increase in cellular thymidine incorporation (6820
52 vs. 5151 308 cpm/106 cells; P < 0.02). Cellular Na transport
(measured as 22Na uptake) was increased in the CRH cells when
compared with N, being 733 47, 886 111 and 1026 147 cpm/l ,000
cells in CRH cells at 1, 3 and 120 minutes, respectively, vs. 353 36,
469 31 and 549 41 cpm/1,000 cells in N cells (P <0.05 for each time
point), that is, an increase in Na transport in CRH cells of 107, 88 and
87%, respectively. Administration of amiloride inhibited Na uptake in
N cells by approximately 50% and completely suppressed the excess
Na uptake in CRH cells to that observed in normal; that is 147 33, 224
91 and 174 86 cpm/1 ,000 cells in CRH cells at 1, 3 and 120 minutes,
vs. 181 71, 164 57 and 238 85 cpm/l ,000 cells in N cells (P = NS
at each time point). The results suggest that enhanced tubular cell
growth in CRH is maintained from the in vivo setting to the in vitro cell
culture system. Increased cellular Na transport in CRH is demonstrated
to be via Na-H exchange by virtue of its reversion to normal in the
presence of amiloride. Taken in conjunction with data from our
previous micropuncture and electron microprobe experiments, the
results support the view that in established CRH in vivo, the hyper-
trophic response is limited by growth inhibitors which act primarily or
secondarily by an alteration in epithelial transport. In vitro, the effect of
these factors is removed, allowing an unrestrained stimulatory growth
response, accompanied by enhanced Na transport.
Anti-endothelial cell antibodies (AECA) and their functional and his-
tological associations in lupus nephritis. G.J. Perry, T. Roedecker, T.M.
Chan, J.S. Cameron, G. Frampton, Renal Unit, UMDS, Guy's Hospi-
tal, London, United Kingdom. Anti-endothelial cell antibodies have
been well documented in SLE. Their functional properties and histo-
logical associations are mainly unknown. Twenty-two patients with
biopsy-proven lupus nephritis were studied. AECA, anticardiolipin
(ACA), anti-dsDNA antibodies (DNA) and serum complement levels
were measured at the time of biopsy and subsequently in remission.
Protein S and von Willebrand factor, markers of endothelial cell
function, were also measured. Renal biopsies were scored for active
and chronic damage. AECA were present in 80% of patients biopsied
and changes in AECA levels reflected disease activity to the same
degree as dsDNA antibodies and C3 levels whereas C4 levels and ACA
did not. Active disease was associated with elevated levels of von
Willebrand factor and reduced levels of Protein S. There was no
association demonstrated between AECA and histological scores of
activity or chronicity. AECA reflect disease activity in a similar fashion
to dsDNA antibodies. The high incidence of AECA with active lupus
nephritis and their association with serological markers of endothelial
cell injury indicate that they may be an important factor in the
pathogenesis of lupus nephritis.
Effect of a water load on urinary excretion of osmoprotectants. P.
Sizeland, S. Chambers, M. Lever, L. Bason, R. Robson, Departments
of Nephrology, Infectious Diseases and Biochemistry, Christchurch
Hospital, New Zealand. In vitro studies using cell-culture have shown
a rapid response of the kidney osmoprotectant system to different
osmotic conditions. We have developed sensitive assays capable of
accurately measuring the osmoprotectants glycine betaine (GB) and
sorbitol (5) in plasma and urine. This study was designed to measure
changes in GB and S in plasma and urine in response to an acute water
load (20 mI/kg) and involved healthy males. Plasma and urine samples
were collected at regular and frequent intervals during the study period
and subsequently analyzed for plasma GB and urine minute volume,
urea, GB and S. The rate of urinary excretion of GB in 4/6 and S in 5/6
subjects changed in parallel with urinary urea excretion, with an initial
increase preceding maximum urine minute volume, followed by a
gradual return to baseline values. There was no change found in plasma
GB concentration during the study period. We conclude that the
osmoprotectants GB and S are components of a physiological and
dynamic system, at least in response to an acute water diuresis.
Comparison of intravenous and oral alfacalcidol in the treatment of
secondary hyperparathyroidism in hemodialysis patients. W. T. Lee, J.F.
Collins and T. Cundy, Department of Medicine, Auckland Hospital,
Auckland, New Zealand. High dose pulse intravenous alfacalcidol can
suppress parathyroid hormone (PTH) levels independent of serum
calcium (Ca) in haemodialysis patients with secondary hyperparathy-
roidism. To determine the optimal schedule of administration of alfa-
calcidol, we conducted a randomized prospective crossover study of
high dose pulse oral and intravenous alfacalcidol on 12 hemodialysis
patients on low Ca dialysate (1.2 mmol/liter). Patients received a 6
weeks course of oral alfacalcidol (4 3 x /week) or intravenous
alfacalcidol (4 sg 3 x/week) with a washout phase before they were
crossed over. Levels of iPTH, ionized Ca and total Ca were obtained
weekly. The alfacalcidol dose was reduced if the total Ca level
exceeded 2.7 mmol/liter. There was a significant reduction in iPTH (P <
0.001) and a significant increase in ionized Ca levels (P < 0.001) with
both intravenous and oral alfacalcidol treatments.
iPTH
Treatment Baseline
(±sEM) Ionized Ca (±5EM)
Treatment Baseline Treatment
Intravenous 28.5 (±2.9) 22.0 (±3.0) 1.24 (±0.01) 1.37 (±0.04)
Oral 35.1 (±3.4) 22.0 (±2.5) 1.21 (±0.01) 1.31 (±0.02)
There was no difference in the degree of iPTH suppression between oral
and intravenous alfacalcidol. With both treatments iPTH levels de-
creased before a rise in ionized Ca levels. The doses of alfacalcidol were
reduced in 8 out of 12 intravenous treatments and in 7 out of 12 oral
treatments because of hypercalcemia. High dose pulse oral alfacalcidol
is as efficacious as high dose intravenous alfacalcidol in the suppression
of secondary hyperparathyroidism in hemodialysis patients. This effect
precedes a rise in ionized Ca levels.
VCAM-1 gene expression in rat kidney and cultured glomerular cells.
Di. Nikolic-Paterson, Y. Yu, and R.C. Atkins, Department of
Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
Vascular cell adhesion molecule-i (VCAM-1) is expressed by endothe-
hal cells following cytokine stimulation and acts as a receptor for the
VLA-4 antigen expressed by activated T cells and monocytes. VCAM-l
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is thought to be involved in the extravasculanzation of activated T cells
and monocytes. Little is known about expression of adhesion molecules
in normal or diseased kidney, thus we have studied VCAM-l gene
expression in the rat kidney by Northern blot hybridization using a rat
eDNA probe. Expression of a single species of VCAM-l mRNA (3.4
kb) was detected in total cellular RNA from normal rat kidney.
VCAM- 1 gene expression was most clearly detected in the medulla and
in glomeruli. In some cases, a second higher molecular weight mRNA
species (=3.8 kb) was detected in the medulla. Regulation of glomerular
VCAM-1 gene expression was examined in vitro. A significant increase
in VCAM- 1 mRNA was observed in isolated normal glomeruli following
a 6 hour culture with rhum IL-la (10 U/mI), but this was markedly
reduced at 24 hours. A similar transient upregulation of glomerular
VCAM-l gene expression was seen using LPS (5 gIml) + PMA (1
nglml) stimulation. In addition to endothelial cells, one candidate for
inducible glomerular VCAM-l gene expression is the mesangial cell.
Preliminary studies with a cloned rat mesangial cell line revealed
VCAM-l gene expression following a 6 hour stimulation with
rhumiL-la (10 U/mI). In conclusion, VCAM-l is expressed in the
medulla and glomeruli of the normal rat kidney. Two different forms of
this molecule, which differ in their extracellular portions, may be
expressed in the kidney on the basis of alternate mRNA splicing. The
transient upregulation of glomerular (including mesangial cell) VCAM- 1
expression by proinflammatory stimuli may be one mechanism by
which leukocyte infiltration in the glomerulus occurs.
A novel human antigen (254Ag) associated with pathological and
non-pathological complement C5b-9 deposits. M. Polihronis, J. Macrae,
J. Saunders, M. O'B,yan, D. Power, A. d'Apice, B.F. Murphy,
Departments of Nephrology and Clinical Immunology, St. Vincent's
Hospital, Fitzroy, Australia. An IgGi monoclonal antibody (mAb 254)
was raised against pathological glomerular basement membrane from a
patient with membranous glomerulonephritis. 254Ag was found to
co-localize exactly with SC5b-9 (components and neoantigen) in gb-
merular immune deposits and areas of glomerular sclerosis in a pro-
spective study of 50 renal biopsies. 254Ag is absent from normal
glomeruli but is invariably detected in the media of normal muscular
arteries, the portal tracts and capsule of normal liver and the splenic
capsule and trabeculae; in all of these sites it is associated with small
amounts of co-localized C5b-9. Detergent treatment of tissues partially
removes SC5b-9 and 254Ag, but both are resistant to treatment with
high salt, acid and denaturing buffers. 254Ag was not detected in normal
human plasma or zymosan activated human serum and mAb 254 does
not react with purified SC5b-9 or C5b-9(m) complement complexes
generated in vitro. Extraction of liver capsule by with sodium dodecyl
sulphate produces a soluble preparation containing SC5b-9 and 254Ag
by dot blot analysis. Preliminary western blotting data suggest that
254Ag may represent an epitope on the highly polymenzed form of C9
seen in membrane bound C5b-9. As such it may be the first reagent able
to distinguish membrane bound C5b-9 [C5b-9(m)] from the soluble
non-lytic SC5b-9 form.
Immunogenetic studies of IgA nephropathy. J.F. Knight, G. Ng, Y.
Zhang, C.M. Artlett, M. Falk, and L.P. Roy, Renal Research Labora-
tories, The Children's Hospital, Camperdown, Australia. IgA nephrop-
athy is the most common cause of glomerulonephritis in Australia. Its
reported genetic associations are with HLA B35, DR4 and DQw8, with
polymorphisms of components of the complement pathway (C2, C3, Bf,
C4A, C4B and C7) and with restriction fragment length polymorphisms
(RFLPs) of the p-switch, a1-switch and a2-switch regions of the
immunoglobulin heavy chain gene. These associations are observed in
some populations but not in others. As part of an ongoing study of
Australians with IgA nephropathy, plasma samples and DNA extracted
from peripheral blood white cells of 70 patients and 210 healthy blood
donors were examined for genetic heterogeneity at some of the loci
listed above. No associations were observed with C2, C3 or Bf plasma
protein polymorphisms. The patient group did however show an
increased incidence of C4B heterozygous null phenotype: 15/70 (21%)
vs. 20/210(9%); P = 0.01; y = 6.16). C4B homozygous null phenotype
was also increased: 6/70(8%) vs. 7/210(3%), but did not reach statistical
significance. The gene frequency for C4B null was 0.084 in controls and
0.193 in patients (P = 0.0007, = 11.4). C4A heterozygous null
phenotype, on the other hand, was more common in controls (67/191;
35%) than in patients (11/70; 16%): P = 0.004; = 8.25. C4A
homozygous null phenotype was similar in both groups. The gene
frequency for C4A null was 0.157 in patients and 0.351 in controls (P =
0.026 y = 4.93. All statistical analyses were performed with Yates'
correction. Southern blots of genomic DNA cut with the restriction
enzyme Sst I were hybridized with a cDNA probe which has sequence
homology with both the z-switch and the a1-switch regions of the
immunoglobulin heavy chain gene. No difference was seen between
patients (N = 66) and controls (N = 196) in the distribution of
polymorphisms at these loci. This study demonstrates that in this group
of Australian patients, IgA nephropathy is associated with an increase
in C4B null phenotype and a decrease in C4A null phenotype. The other
associations reported in other centers were not apparent.
Endoglin, a l8OkD endothelial cell and macrophage restricted differ-
entiation molecule. Phillip J. O'Connell, Adrienne McKenzie, Nella
Fisicaro, Steven P. Rockman, Martin J. Pearse, and Anthony J.F.
d'Apice, Departments of Nephrology and Clinical Immunology, St.
Vincent's Hospital, and the Departments of Nephrology and Haema-
tology, Royal Melbourne Hospital, Victoria, Australia. Endothelial
cells (EC) have been shown to play an active role in many immunolog-
ical functions including hemopoesis, the homing of lymphocytes to
specific organs and the migration of granulocytes and monocytes to
areas of inflammation. ECs also share many of the characteristics of
myelomonocytic cells including antigen processing and presentation
and secretion of interleukin 1, interleukin 6, and proteases. As would be
expected from the sharing of various functions, ECs and myelomono-
cytic cells share many surface molecules. This report describes a mAb,
RMAC8, generated by immunizing Balb/c mice with cultured human
umbilical vein endothelial cells (HUVE). The molecule recognized had
a Mr of l8OkD non-reduced, 95kD after reduction and 66 kD in its
reduced and N-deglycosylated form. The p1 of the reduced molecule
was 4.8—5.0. Sequential immunoprecipitation studies with the mAb
44G4, which recognizes the 0- and N-glycosylated homodimer endog-
lin, showed that both mAb recognize the same molecule on PMA
stimulated U937 cells (human monocyte/macrophage cell line). The
distribution of the RMAC8 recognized molecule was the same as that
described for endoglin, that is, arterial and venous endothelium, my-
ebomonocytic and pre-B leukemia cells and cell lines, however, unlike
44G4, RMAC8 also reacted weakly with monocytes and strongly with in
vitro differentiated macrophages and peritoneal macrophages. This
distribution of endoglin was confirmed by Northern blot analysis using
a full length endoglin cDNA probe. These studies suggest that endoglin
is a differentiation marker on macrophages where the epitope recog-
nized by 44G4 is hidden.
Epidermal growth factor (EGF) production by rat mesangial cells. D.J.
Nikolic-Paterson, H.C. Ramm, T. Ootaka, N. Kraft, and R.C. Atkins,
Department of Nephrology, Monash Medical Centre, Clayton, Victo-
ria, Australia. EGF production in the kidney is restricted to the luminal
surface of specific tubular epithelial cells, and therefore only circulating
EGF has access to the mesangium. Cultured mesangial cells have been
shown to express EGF-receptors and to proliferate in response to
exogenous EGF. We investigated whether cultured mesangial cells
could also synthesize EGF which could act as a potential autocrine
growth factor. Northern blot analysis of total cellular RNA from cloned
rat and mouse mesangial cell lines (1097 and B2A2) demonstrated the
expression of a single =5 kb EGF mRNA species. EGF gene expression
was observed under conditions of serum starvation (0.5% FCS for 3
days), rapid growth, and confluency. EGF protein production by rat
and mouse mesangial cells cultured on glass slides was detected with a
rabbit anti-mouse EGF polycbonal antibody by the immunoperoxidase
method. Also, EGF protein production by mesangial cells cultured in 96
well trays was detected with the polyclonal antibody using an ELISA
technique. Furthermore, preliminary Western blot studies revealed the
presence of 3 EGF species (roughly 60, 50, and 10 kD) in mesangial cell
lysates. To investigate whether EGF production by mesangial cells was
involved in an autocrine pathway, rabbit anti-mouse EGF antibody was
added to cell lines in culture. Antibody addition was able to neutralize
the stimulatory effect of exogenous mouse EGF on both cell lines, but
failed to inhibit baseline proliferation. In conclusion, this study demon-
strates that cultured rat and mouse mesangial cells synthesize EGF
under various growth conditions. The inability of anti-EGF antibody to
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inhibit mesangial cell proliferation suggests two possibilities: (1) EGF
derived from mesangial cells is not processed as a functionally active
molecule, or (2) the antibody is unable to compete with the mechanism
of autocrine EGF utilization.
Quantitative and semi-quantitative estimation of fibronectin mRNA
splice variants in cultured human mesangial cells using polymerase chain
reaction. D.A. Power, N.E. Haites, M.C. Jones, N. McKay, Depart-
ments of Nephrology and Clinical Immunology, St. Vincent's Hospital,
Fitzroy, Australia. Fibronectin is a glycoprotein present in extracellular
matrix (ECM), possessing three known sites for adherence to cells.
Two of these can be removed by alternating splicing in the IIICS region
of the molecule; the best described cell attachment site, the only one
bearing an RGD sequence, lies between two further alternative splice
sites, EIILA and EII1B. In order to study the influence of cytokines on
synthesis and splicing of fibronectin by cultured human mesangial cells,
methods were developed for the quantitative and semi-quantitative
estimation of mRNA transcript numbers. Transcript numbers for two
splice variants of fibronectin were determined quantitatively using an
internal control; semi-quantitative estimation of 4 of the 5 splice
variants in the IIICS region was also pet-formed. In the quantitative
assay, primers flanking the EII1A domain were used to amplify RNA
DNA hybrids by polymerase chain reaction (PCR). In order to quanti-
tate transcript numbers, a control species was produced by excising the
mid-portion of a cDNA probe for fibronectin between two sites for the
restriction enzyme Xho. Using radiolabeled primers and quantitative
PCR, it was found that approximately 2/3 transcripts lacked EIIIA in
both cell types. The mean number of fibronecting transcripts per cell
was approximately 4.6. Interassay coefficients of variation for the assay
were 14% for transcripts with EIIIA and 10% for the dominant species.
For semi-quantitative assessment of splice variants in the LICS region,
primers flanking this region were used to amplify reverse transcribed
RNA from mesangial cells and the products separated on agarose gels.
The percentage of each was estimated by densitometry. These studies
demonstrate the absolute or relative number of RNA splice variants in
a cell can be determined using quantitative PCR.
Inhibition studies of the functional properties of neutrophil lysosomal
enzymes. Linus Chang, and Judy Savige, Department of Haematology,
Heidelberg Repatriation Hospital, Banksia Street, Heidelberg West,
Victoria, Australia. Anti-neutrophil proteinase-3 (29kd), anti-Myelo-
peroxidase and anti-elastase are three members of a novel class of
autoantibodies against lysosomal enzymes present in human neutrophil
cytoplasmic granules and are associated with systemic vasculitis.
Untreated cases of Wegener's granulomatosis, microscopic polyarteri-
tis, and crescentic glomerulonephritis may result in renal failure.
Immunosuppressive regimes drastically improve prognosis of these
conditions which are associated with systemic vasculitis, implicating
involvement of the autoantibodies in the pathogenesis of these diseases.
To investigate whether functional and immunogenic properties share
common epitopes, we studied the inhibitability of these enzymes by
their respective antibodies. Neutrophil proteinase-3 is a serine esterase
and its activity was measured by the cleavage of alpha-naphthal acetate
by neutrophil granule extract. Myeloperoxidase activity was measured
by two methods: pet-oxidation of guaiacol by hydrogen peroxide(H202), and peroxidation of monochlorodimedon by H202 in the
presence of chloride ions. Elastase activity was measured by fluorimet-
nc assay of the hydrolytic product of N-Succ ala3 amido-methyl
coumarin. Inhibition of these enzymes was performed by incubating
positive (assessed by Enzyme Linked Immunosorbent Assay) patient
sera or immunoglobulin with the enzymes in liquid phase or first
incubating sera or immunoglobulin with the respective enzymes pre-
coated on Dynatech plates before activity assays. In all three enzymes
no inhibition of catalytic activity was observed in either the liquid phase
or solid phase inhibition procedure. These results suggest that catalytic
and immunogenic properties of these enzymes share very little or have
no common epitopes.
Production of pro-inflammatory cytokines by resident glomerular cells.
Y. Yu, D.J. Nikolic-Paterson, and R.C. Atkins, Department of
Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
This study has investigated whether resident glomerular cells, in the
absence of an inflammatory infiltrate, are capable of producing pro-
inflammatory cytokines in response to specific stimuli. Glomeruli were
isolated from Sprague-Dawley rat kidneys (2—4 months old) by differ-
ential seiving, cultured for 6 or 24 hours in RPMI/l0% FCS with 10 U/mI
recombinant human IL-I a or 5 g/ml LPS plus I ng/ml PMA, and total
cellular RNA prepared. Northern blot analysis failed to detect IL-1J3
gene expression in normal kidney or freshly isolated glomeruli. How-
ever, a 6 hour culture with IL-la induced expression of a single IL-l/3
mRNA species (1.8 kb) which was downregulated by 24 hours. LPS +
PMA stimulation also caused an induction of IL-l/3 mRNA which was
sustained at 24 hours of culture. IL-6 gene expression was not detected
in fresh renal tissue, but was clearly evident in glomeruli following a 6
hour stimulation with IL-la or LPS + PMA. In contrast to IL-l/3 gene
expression, levels of IL-6 mRNA (=1.3 and 2.4 kb) remained elevated
at 24 hours in response to both stimuli. In order to check that cytokine
mRNA production was not due to contaminating blood cells, kidneys
were perfused in situ with PBS. Comparable levels of both IL-i/I and
IL-6 mRNA species were evident in glomeruli prepared from perfused
and non-perfused kidneys following in vitro stimulation. To establish
whether culture alone could induce cytokine expression, glomeruli
were cultured in RPMI/10% FCS, and only a very faint IL-6 mRNA
signal was detected. In conclusion, resident glomerular cells have been
shown to express pro-inflammatory cytokine genes in response to
specific pro-inflammatory stimuli. This may be an important mechanism
in the induction of glomerular leukocytic infiltration by chemotaxis and
expression of adhesion molecules. Also, such cytokine production may
regulate the function of other resident glomerular cells.
Function of increased ICAM-1 expression on interferon gamma (IFNg)
stimulated mononuclear phagocytes. P. Hutchinson, N. Kraft, and R.C.
Atkins, Department of Nephrology, Monash Medical Centre, Clayton,
Victoria, Australia. ICAM-1 is a cell surface glycoprotein found on
vascular endothelium and epithelial cells, but is only weakly expressed
on resting leukocytes. It is a ligand for the LFA-l molecule and is a
critical component of T-cell activation in some immunological reac-
tions. As IFN-g is known to increase ICAM-1 expression on some cells
and to potentiate macrophage accessory activity, we examined it's
effect on ICAM-l expression on a variety of phagocytes. Addition of
IFNg (1000 U/ml) led to a rapid induction of ICAM-l (2—6 hours) on the
myelomonocytic lines U937 and Rc2A with a plateau response at day
one and maintained to day 3 (U937: N = 7, 361 104%; Rc2A: N = 6,
338 146%). The IFNg response was dose-dependent to 300 U/mI.
Blood derived monocytes cultured in teflon bags for three days showed
an increase in ICAM-1 of 282 121% (N = 5), with an early response
apparent at 2 hours. PHA stimulation of T-cell proliferation was
increased when IFNg treated Rc2A cells were used as accessory cells
compared to non-treated cells, but there was no increased blocking by
anti-ICAM-l antibody. However, the allogeneic response of the T-cells
to IFNg-treated Rc2A cells was significantly greater than against
untreated Rc2A cells and was inhibited by anti-ICAM-1 antibody. This
may indicate specific roles for the increased ICAM-1 expression on
phagocytic cells. Interleukin-l production by both the IFNg treated and
control Rc2A cells was minimal, while addition if recombinant IL- 1 and
IL-6 to the allogeneic response did not consistently increase the
proliferation of the T-cells against the control Rc2A cells to the level of
the IFNg treated cells, implying a limited role of these cytokines in the
heightened response.
Maintenance of the integrity of C8 and C9 of the complement mem-
brane attack complex in the sera of patients with SLE. B.A. Pussell, C.
Morris, L. Milis, V. Timmermans and J.A. Charlesworth, Department
of Nephrology, Prince Henry Hospital, Sydney, NSW, Australia.
Activation of the complement cascade is a hallmark of systemic lupus
erythematosus (SLE) with predominant depletion of classical pathway
components by ongoing activation. In addition, genetic deficiencies of
early components are frequently associated with SLE or SLE-like
illnesses. In contrast, deficiencies of the membrane attack pathway do
not have an association with SLE but with infection by intracellular
microorganisms, especially Neisseria. However, involvement of the
membrane attack complex (MAC) in the mediation of renal injury has
been reported in both experimental animal models of glomerulonephri-
tis and in human kidneys using immunofluorescence techniques. In
order to test the integrity of the MAC in patients with SLE, we used an
in vitro assay of the functional activity of C8 and C9. Sheep red blood
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cells(E) coated with antibody(A) were used to activate complement in
serum deficient in C8 and to form stable EACI-7 cells. The MAC was
then completed by the provision of C8 and C9 in very dilute normal or
test serum and cell lysis estimated by optical density. All 15 SLE sera
tested gave identical lysis to normal sera despite levels of low CH5O, C3
and C4. We conclude that functional activity of C8 and C9 of the MAC
of complement is retained in the sera of patients with SLE despite
evidence for classical pathway activation. Such a finding has implica-
tions for the sites of complement activation in SLE and the particular
complement components involved in tissue injury.
Western blot analysis of membrane antigens recognized by anti-
endothelial cell antibodies (AECA) in SLE. G.J. Perry. N. Gregson,
T.M. Chan, J.S. Cameron, G. Frampton, Renal Unit, UMDS, Guy's
Hospital, London, United Kingdom. We have demonstrated that
AECA occur in 35% of patients with systemic lupus erythematosus
(SLE). The target epitopes have not been fully characterized. The
endothelial cell line EAHy 926 (gift of Dr. C-J Edgell) was screened for
the presence of the autoantigen(s) using a cell-based ELISA and
compared with the standard human umbilical vein endothelial cells. The
binding correlation between the two cell populations was r = 0.72 (P <
0.001). This suggested that the autoantigen(s) was present on both cells.
Plasma membranes from EAHy 926 cells were prepared and used for
Western blotting with AECA positive SLE sera. Multiple bands could
be identified. SLE patients with and without nephritis were compared.
In general, a band of approximate molecular weight 66 kD was present
in both groups and was the most common band detected. Other bands
could be detected which were predominantly associated with nephritis.
This provides further evidence for the autoantigens recognised by
AECA and suggests that some antigens may be relevant in the patho-
genesis of lupus nephritis.
Altered in vitro lymphocyte response in childhood nephrotic syndrome.
1K. Hewitt, A.K. House, f.M. Potter, B.F. Kinnear, Department of
Nephrology, Princess Margaret Hospital for Children, Perth, WA.,
Australia. The immune system, and disturbed T lymphocyte function in
particular has been implicated in the pathogenesis of childhood idio-
pathic nephrotic syndrome (INS). As this disorder is commonly respon-
sive to steroid therapy, we set out to determine whether in vitro
suppression of lymphocyte blastogenic response to the mitogen PHA
could predict the clinical outcome. Nine children with INS (aged
27—15.7 years) were studied. Controls consisted of 9 healthy children
(aged 1.9—15.3 years). Lymphocytes were isolated from heparinized
blood via density gradient centrifugation, washed and suspended in
phosphate buffered saline supplemented with 15% heat inactivated fetal
calf serum. Aliquots of 100 sI were incubated with PHA (15 sg/ml) and
prednisolone (concentrations 0—280 mol) then labeled with tritiated
thynsidine. Thymidine incorporation into DNA was measured by liquid
scintillation counting. Suppression of lymphocyte blastogenesis was
expressed as the inhibitory dose 50% (ID50) of prednisolone calculated
from the prednisolone dose response curve. Lymphocytes from ne-
phrotic patients showed in vitro resistance to prednisolone suppression
with ID50 77.8 18.5 (mean SE) compared with healthy controls ID50
6.8 3.2 (P = 0.0037). This study further implicates lymphocyte
function in the mechanisms underlying INS. However, the study did
not reliably predict clinical response of INS to prednisolone.
Effect of dietary NaCI on intramyocardial and renal vascular and
glomerular lesions in hypertension. D.T. Liu, P. Kincaid-Smith, and
J.A. Whitworth, Department of Medicine, St. George Hospital, Uni-
versity of New South Wales, and Department of Nephrology, Royal
Melbourne Hospital, Australia. To examine the hypothesis that high
levels of dietary NaCI aggravate hypertension-associated vascular
lesions, a study was carried out in DOCA, two kidney one clip (2KIC)
hypertensive and normotensive control Sprague-Dawley rats. Animals
in each group (N = 8—10) received regular, high or low NaC1 diet (NaD)
for 8 weeks. SBP was measured via tail cuff and metabolic balance was
measured in metabolic cages weekly. At the end of the study, hearts
and kidneys were harvested for histologic study. Diet did not affect SBP
in control rats. High NaD significantly increased SBP in DOCA rats,
but not in 2K1C rats.
Na Diet Control DOCA 2K1C
SBP Regular 95 2 118 4 178 9
mm Hg High 99 3 143 a 172 7
at week 8 Low 103 3 113 5 173 7
a P < 0.01 vs. regular and low Na diet
Urinary Na excretion was significantly elevated by Na loading in
control, DOCA and 2KIC rats (P < 0.01). Histologic studies showed
high NaD caused a lower ratio of lumen to outer diameter of intramy-
ocardial arteries in DOCA (high NaD 0.33 0.02 vs. regular 0.39 0.02
and low NaD 0.41 0.02) and 2KIC rats (high NaD 0.30 0.02 vs.
regular 0.39 0.02 and low NaD 0.39 0.02, P < 0.005). It also caused
a higher percentage of glomerular lesions in DOCA (high NaD 14%
range 1—36% vs. regular 1% range 0—3% and low NaD 1% range 0—4%,
P < 0.05) and 2K1C rats (high 21% range 1—43% and regular NaD 22%
range 0—44% vs. low NaD 5% range 0—40%, P < 0.05). For interlobular
arterial lesions, high NaD resulted in a higher score in 2K1C rats (high
NaD 307 range 200—314 vs. low NaD 200 range 150—250, P < 0.05). In
conclusion, high NaC1 diet caused more severe vascular and glomerular
damage in both salt-dependent and salt-independent hypertension,
although it has no effect on normotensive animals. This effect was
independent of blood pressure.
Analysis of pH recovery after exercise in human and rat hypertension
suggests increased proton efflux. G.J. Kemp, C.H. Thompson, D.J.
Taylor, G.K. Radda, and J.G.G. Ledingham, MRC Biochemical and
Clinical Magnetic Resonance Unit, John Radcltffe Hospital, Oxford,
United Kingdom. Increased NaJH exchange in vascular smooth muscle
and other cells may be important in hypertension. In the spontaneously
hypertensive rat (SHR) and human hypertension, exercising skeletal
muscle acidifies less than controls, and in SHR this difference is
abolished by amilonde. In skeletal myoblasts from SHR, Na/H an-
tiporter activity is increased, but its reported characteristics in vitro
differ widely and little is known about its activity in vivo. We present a
novel analysis of pH recovery after exercise which, by calculating
proton production due to phosphocreatine (Per) resynthesis and the
titration of cellular buffers, allows quantification of apparent proton
efilux. Leg muscles of anesthetised SHR and Wistar-Kyoto (WKY) rats(N = 5 each) were studied by 31P magnetic resonance spectroscopy in
a 7 T magnet for 15 minutes after sciatic nerve stimulation (10 Hz for 2
mm), and spectra used to calculate [PCr] and pH. In SHR, the early (0—2
mm) rate of pH recovery was greater than in WKY (0.21 vs. 0.11 pH
unit min', respectively, P < 0.01). At the start of recovery proton
efflux was greater in SHR (17 vs. 10 mmol kg wet wt' min', P < 0.01)
despite the higher pH (6.30 vs. 6.17, P < 0.01). During recovery, proton
efflux was negatively related to intracellular pH, with a slope which was
increased in SHR (—26 vs. —11 mmol kg . wet wt . min pH uniF',
P < 0.01). In humans, similar analysis of recovery from forearm
exercise suggests that initial proton efflux is increased in hypertensive
patients (N = 9) compared to controls (N = 12; 13 vs 8 mmol 1' min'),
despite a higher pH (6.55 vs. 6.40).
Proteinuria and its assessment in normal and hypertensive pregnancy.
E. Gallery, V. Kuo and G. Koumantakis, Departments of Renal
Medicine, Biochemistry and Obstetrics, Royal North Shore Hospital,
St. Leonards, NSW, Australia. Pregnancy-associated hypertension
(P-AH) is a common complication of pregnancy. Proteinuria is a
hallmark of its severity, but methods of reporting it are poorly described
and standardized, the most commonly recorded method being dipstick
analysis of a random urine sample. The purposes of this study were: (1)
to determine 24 hour urinary protein excretion rates in normal human
pregnancy; (2) to assess the reliability of assessment of proteinuria by
dipstick measurement. At 17 to 20, and at 33 to 36 weeks of pregnancy,
174 normal women collected a 24 hour urine sample, whose volume,
protein and creatinine concentrations were measured. The result for
protein was compared with dipstick analysis of an early morning
mid-stream urine sample collected at the end of the 24 hour period.
Sixty-eight consecutive inpatients admitted to the antenatal ward with
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hypertension and positive urine dipstick tests for protein underwent the
same procedure. The inter-observer variability for 66 hospital staff
members in dipstick analyses of urine samples of known protein content
was assessed. The upper 95% confidence limit of normal was below 0.2
g/24 hours, at both stages of pregnancy investigated. A high proportion
of false positive and false negative results was found with dipstick
analyses. Assessment of proteinuria by dipstick gave an 18% false
positive rate, and a 40% false negative rate for samples with 0.03 g
albumin/lOO ml urine. Even in the presence of 0.1 g/100 ml, the false
negative rate was 7%, while the concentration of protein was signifi-
cantly underestimated in some 20% of samples with 0.5 g/lOO ml.
Dipstick urinalysis cannot be relied upon either to detect or to exclude
the presence of proteinuria in pregnant women.
Metabolic effects of angiotensin converting enzyme inhibitors (ACE'Is)
in healthy volunteers. MO. Pratt, N.J. Lewis-Barned, and R.J. Walker,
Department of Medicine, Otago Medical School, Dunedin, New
Zealand. Insulin resistance is a etiological factor in non-insulin-depen-
dent diabetes mellitus, hypertension, obesity and accelerated athero-
sclerosis. Captopril may improve insulin sensitivity in hypertensive
individuals. No studies have compared the effect of different ACEL's
and their effect on insulin sensitivity in a normal population. Ten
healthy volunteers (8 males, 2 females) were enrolled in a randomized,
single-blind cross over study comparing captopril (6.25 mg twice a day
for 28 days) with enalapril (5 mg per day for 28 days) with a 28-day wash
out period between drugs. All 10 subjects completed the trial with no
change in their dietary habits or exercise level during the study. Insulin
sensitivity (M value mg/kg/mm) was measured using the euglycemic
hyperinsulinemic clamp at the start and completion of each four week
drug treatment. Blood pressure, plasma biochemistry, glucose and
insulin were monitored throughout the study. The insulin sensitivity,
insulin sensitivity index (1ST), fasting insulins and plasma glucose
showed no first or second order carryover effects.
Day 0 Day 28
M value Captopril
Enalapril
6.3
6.1
0.6
0.4
5.6
5.4
0.7 mg/kg/mm
0.5 mg/kg/mm
ISI Captopril
Enalapril
8.7
8.0
1.3
0.8
7.4
7.4
1.1 M/sU/ml%
1.0 M/U/ml%
Insulin Captopril
Enalapril
7.9
9.7
0.9
1.5
11.5
11.5
2.2 zU/ml
1.4 U/ml
Glucose Captopril
Enalapril
4.3
4.3
0.1
0.1
4.1
4.2
0.1 mmol/liter
0.1 mmol/liter
The decreased M value and 151 demonstrated just failed to reach
significance (95% confidence range P < 0.056). The fasting insulin
increased significantly (P < 0.05), and the fasting glucose decreased but
failed to reach significance. There was no significant difference demon-
strated between captopril and enalapril. Of considerable interest is a
decreased 151 which is opposite to the trend seen in hypertensive
individuals. Explanation for this can't be attributed to factors known to
modulate insulin sensitivity or to the actions of captopril alone.
Urinary red blood cell and cast excretion in normal and hypertensive
human pregnancy. E.D.M. Gallery, M. Ross, andA.Z. Gyory, Depart-
ment of Renal Medicine, Royal North Shore Hospital, St. Leonards,
NSW, Australia. Although the well-recognized pregnancy changes in
renal blood flow, cellular function, tubular fluid composition and flow
rates may cause altered excretion rates of formed elements in the urine,
relatively little attention has been paid to this in normal pregnancy. The
urinary white cell excretion is known to be increased, with loss of the
usual relationship between pyuria and urinary infection. Whether the
same is true for other formed elements is unknown. This study's
purpose was to determine normal values for excretion of erythrocytes
and casts, and to establish whether they became abnormal in women
who developed pregnancy-associated hypertension (P-AH). Study sub-
jects were 174 continuously normotensive pregnant volunteers (N), 22
who developed P-AH, and 8 with chronic essential hypertension
(CEH). Early morning mid-stream urine samples were collected at 17 to
20 and at 33 to 36 weeks' amenorrhea, after insertion of a vaginal
tampon. Urinary microscopy was performed by standard techniques
(Kesson et al: Lancet 2:809, 1978). The 95th percentile for concentra-
tion of erythrocytes was 2500/ml and for casts 30/ml in normal
pregnancy. Values for those who developed P-AH and for the small
group with CEH were within these limits.
ACTH hypertension in the rat: Role of sodium chloride. Ming Li and
Judith A. Whitworth, Department of Medicine, St. George Hospital,
University of New South Wales, Australia. Adrenocorticotrophin
(ACTH) produces adrenally dependent increases in both blood pressure
and salt (NaC1) appetite in the rat. ACTH treatment induced a large
increase in blood pressure in the intact rat on nonnal and low sodium
diet. The present study examines the effect of free access to a high
intake of NaC1 on ACTH hypertension in the rat to test the hypothesis
that high NaCI intake would amplify the rise in blood pressure. Either
water or 1% NaCI were offered to sham or ACTH treated Sprague-
Dawley rats. Subcutaneous injections of synthetic ACTH (0.5 mg/kg/
day) for 10 days caused large increases in the intake of both 1% NaCI
(+240 6mI/day) and water (+45 4mI/day), urine volume (1% NaCI
+ ACTH +182 4 mI/day, ACTH + water + 36 2 mI/day), adrenal
weight (ACTH + water 176 18, ACTH + 1% NaCl 367 129 mg/lOO
g body wt) and maximum systolic blood pressure (SBP) (ACTH +
water +18 5mm Hg; 1% NaCl + ACTH +16 3 mm Hg). The rise
in systolic blood pressure following ACTH in water drinking rats was
higher than that in animals on 1% NaCI at treatment day 10 (ACTH +
water 116 5; 1% NaCI + ACTH 104 6 mm Hg; P < 0.05). This
difference may reflect the thoracicoabdominal edema seen in 1% NaCI
drinking rats on ACTH. Three rats developed very low blood pressure
(55, 75 and 90 mm Hg, respectively) by treatment day 8 through 10,
suggesting compromised cardiac function. ACTH treatment in rats
offered 1% NaC1 produced significant increases of urinary sodium and
potassium excretion probably reflecting the huge increase of urine
volume compared to ACTH treatment in water drinking rats, or sham
injected rats on 1% NaCI. Plasma potassium in ACTH treated 1% NaCI
drinking rats was significantly lower than in ACTH treated water
drinking rats (ACTH + water 3.7 0.2 mmol/liter ACTH + 1% NaCI
2.3 0.4 mmol/liter, P < 0.001), but there was no difference in plasma
sodium concentration. Thus, free access to NaCI in ACTH treated
Sprague-Dawley rats did not potentiate the hypertension, but was
associated with edema in some animals.
Clinicopathological course of microscopic polyarteritis (MPA). E.A.
D'Almeida, R.S. Nanra, S.C. Carney, A.H.B. Gillies, B.F. Jones, and
P.R. Trevillian, Nephrology Unit, John Hunter Hospital, Newcastle,
NSW, Australia. Data from 27 male and 20 female patients, age 51 19
years, with MPA, and followed for 3 to 180 months (median 26), were
reviewed retrospectively. The diagnosis of MPA was made on the renal
biopsy finding of a focal proliferative glomerulonephritis with no
immune deposits detected by immunofluorescence. Seventy percent of
biopsies (N = 40) had cellular crescents, and 18% had crescents in
>50% of glomeruli. Vasculitic lesions were absent in all biopsies.
Histological activity grade on a scale of 0 to 3 was: 0 = 2%, 1 = 37%,
2 = 41% and 3 = 20%. Chronicity grade on a scale of 0—2 was: 0 = 7%,
= 81% and 2 12%. The major nonrenal manifestations were: fever
52%, musculoskeletal 39%, weight loss 38%, vasculitic rash 22%; other
organ involvement occurred in 2 to 7% of patients. Renal manifestations
were: proteinuria 100%, hematuria 96%, BP> 150/90 mm Hg 76%, 5Cr
> 0.15 55% (range 0.06—1.17, median 0.17), RBC casts 53%, nephrotic
syndrome 32%, and WBC casts 17%. Serum IgG was elevated in 36%.
Data on treatment were available in 35 patients and consisted of:
low-dose prednisone (<40 mg/day) in 5 patients, and high-dose pred-
nisone (>40 mg/day) in 30 patients with additional cyclophosphamide in
19 patients. Four patients died, 2 commenced maintenance dialysis, and
4 were lost to follow-up. Of the remaining 37 patients, renal function
improved in 37% (median S. 0.39—>0.15), remained stable in 33%
(median Sr 0.ll—>0.l1), and deteriorated in 30% (median Sc,. 0.19—
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>0.37). The predictors of renal deterioration were: elevated serum IgG(P = 0.005), % of glomeruli with active focal lesions (P = 0.026), low
dose prednisone (P = 0.057), histological activity of disease (P =
0.067), and % of glomeruli with global glomerular sclerosis (P = 0.070).
(mean standard deviation; Sr = serum creatinine mmol/liter)
Renal functional abnormalities in association with rheumatoid arthritis
(RA). P. Savvas, L.S. Ibels, AZ. Gyory, and P.M. Brooks, Depart-
ments of Renal Medicine and Rheumatology, Royal North Shore
Hospital, St. Leonards, NSW, Australia. A prospective study was
undertaken to detennine abnormalities in patients with RA, with special
reference to tubular function. Forty-six patients were assessed by
clinical examination, serology, 24-hour urinary protein excretion and
comprehensive one-day renal function testing. All patients fulfilled
revised ARA criteria for RA. RA had been present for 2 months to 49
years (mean 11 years) at the time of study. True serum creatinine
concentration was abnormal in only I patient. Abnormal proteinuria
was detected in 10. Creatinine clearance, when adjusted for age and
sex, as abnormal in 5, Proximal tubule function, assessed by 15 minute
phenol-sulphonphthalein excretion, was abnormal in 15. White cell
excretion rate was elevated in 26. Centrifuged urine microscopy re-
vealed abnormal cast excretion in 35 (waxy in 35, granular in 25, hyaline
in 14). Pyuria and microscopic hematuria were also frequent (24 and 12
patients, respectively). Maximum urinary osmolarity after intranasal
antidiuretic hormone was abnormal in 31, and 43 patients had a defect
in urinary acidification after ammonium chloride load, indicative of
tubular dysfunction. Only 2 patients had entirely normal renal function.
Correlations will be presented with clinical and immunological param-
eters as well as drug intake, especially non-sterOidal anti-inflammato-
ries. Thus, patients with long-standing RA have a very high incidence of
renal functional abnormalities despite normal serum creatinine concen-
trations. These predominantly reflect medullary or tubulointerstitial
disease. This should be acknowledged when prescribing potentially
nephrotoxic drugs in this group. Elevated serum creatinine concentra-
tion alone is the most inaccurate way of assessing renal function in RA
patients.
Calcium-related changes with evolving renal failure. M. Cochran, H.
Morris, Department of Medicine, Flinders Medical Centre, Bedford
Park, Institute of Medical and Veterinary Science, Adelaide, Australia.
The origin of renal secondary hyperparathyroidisni is now becoming
clearer. Recent studies suggest that the primary defect lies with a failure
of adequate production of I ,25D at a relatively early stage of renal
insufficiency. In a cress-sectional study we have measured calcium-
related variables in 180 subjects whose collective range of renal
function spanned normality to severe impairment. The renal function
was categorized from a derived creatinine clearance using age, weight,
and plasma creatinine. The earliest change, at creatinine clearance 70
mI/mm, was a fall in fasting and non-fasting urine calcium excretion,
though the excretion relative to GFR was unaltered. Plasma calcium
and phosphate were unchanged. The serum 1 ,25D was not detectably
lower at this stage, but PTH showed a small rise. As renal function
declined to a creatinine clearance of 30 mI/mm, the plasma calcium
began to fall and absolute urine calcium excretion reached a minimum.
Plasma phosphate decreased slightly and calcium absorption and I ,25D
were clearly decreased. The PTH was mildly elevated. At lower levels
of creatinine clearance, the phosphate increased with the plasma
creatinine, the l,25D level decreased further and PTH was more
elevated. Plasma calcium was reduced but urine calcium increased. The
calcium-related changes at different levels of renal failure are complex,
but the data suggest that phosphate loading is not generally the initiating
factor in decreased production of I ,25D. They also lend support to the
notion of decreased tissue sensitivity to the metabolite.
Effect of recombinant human growth hormone (rhGH) on calcium
regulation in short, slowly growing (SSG) children. G.D. Ogle, A.R.
Rosenberg, and G. Kainer, Department of Nephrology, Prince of
Wales Children's Hospital, Randwick NSW, Australia. Growth hor-
mone (GH) affects calcium homeostasis, but the effects of GH therapy
on calcium regulation in non GH-deficient SSG children are unknown.
We prospectively studied 11 prepubertal SSG children (8 boys and 3
girls) with normal 24-hour GH secretion. Age range was 4.9 to 12 years
(mean 9.6 yr). rhGH was administered subcutaneously in a mean dose
of 0.55 U/kglwk. The results (expressed as means SD) were as
follows:
Baseline 8 weeks 24 weeks
Serum calcium 2.40 0.09 2.40 0.09 2.38 0.09
mmol/liter
Serum phosphate 1.52 0.12 1.62 0.24 1.6 0.22
mmol/liter
Urine calcium 0.063 0.039 0.049 0.049 0.054 0.056
mmol/kg/24 hr
Urine phosphate 13.6 5.0 17.4 10.3 19.0 8.3a
mmol/24 hr N = 10
Serum 1,25 (OH)2
vitamin D3 71.2 38.5 111.8 32.Oa 122.9 49,4b
pmol/liter N = 9 N = 9
Serum calcitonin 85.2 31.6 77.4 39.3 74.0 16.5
pg/ml
Serum 1.96 0.94 1.81 0.71 2.05 0.96
parathyroid
hormone pmol/
liter
a P < b p < 0.02, compared to baseline, by Student's t-test
We have shown for the first time in non GH-deficient children that
rhGH increases 1,25 dihydroxyvitamin D3. This prolonged effect was
not associated with significant changes in other calcium regulating
hormones (however, surprisingly, urinary phosphate increased), and
may have adverse clinical implications.
Comparison of cyprofloxacin with netilmicin for treatment of acute
pyelonephritis: Reducing hospital stay. R.R. Bailey, K.L. Lynn, R.A.
Robson, BA. Peddie, and A.H. Smith, Department of Nephrology,
Christchurch Hospital, Christchurch, New Zealand. The aminoglyco-
side antibiotics are still considered the drugs of choice for the treatment
of severe or complicated urinary tract infections. The 4-quinolones are
challenging the aminoglycosides regarding efficacy and safety. A pro-
spective randomized study was undertaken to compare the efficacy of
cyprofloxacin and netilmicin for the treatment of patients with acute
pyelonephritis requiring hospitalization. Forty-three patients were en-
rolled in the study and 34 (29 women) completed the protocol. Fifteen
of 17 patients treated with cyprofloxacin (100 mg 12 hr. i.v., switching
when clinically appropriate to 250 mg 12 hr. orally) were cured. Fifteen
of 17 treated with netilmicin (2 mg/kg loading dose i.v. and then
adjusted according to drug concentrations and renal function) were
cured. All patients were treated for 5 days. One patient relapsed after
cyprofloxacin and another had a re-infection, while 2 relapsed after
netilmicin. Five of the 6 patients with a urinary tract abnormality were
cured. Side effects were generally mild and rapidly reversible. Patients
treated with cyprofloxacin spent a mean of 3.7 days in the hospital
compared with 5.3 days for those treated with netilmicin. The difference
in duration of hospital stay was statistically significant (P < 0.01). In
summary, both cyprofloxacin and netilmicin proved highly effective and
safe for the treatment of severe acute pyelonephritis.
Hemoclialysis increases serum alpha-2 macroglobulin level indepen-
dently of the membrane used. A. Argiles, PG. Kerr, C. Mion, andR.C.
Atkins, Departments of Nephrology, Monash Medical Centre, Clayton,
Victoria, Australia, and Lapeyronie University Hospital, Montpellier,
France. Beta-2 microglobulin (/32m) has been documented as the major
protein constituent of hemodialysis associated amyloidosis (HDAA).
However, the pathogenesis of HDAA is still unresolved and other
proteins have been implicated. We previously identified alpha-2 macro-
globulin (A2M) in amyloid deposits and suggested that A2m may
participate in the formation and/or maintenance of the deposits. In the
present study we analyzed the influence of the hemodialysis (HD)
procedure and membranes on A2m serum levels. Seven stable dialyzed
patients (3 F, 4 M; 60 2 year old) participated in the study. A2m,
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alpha-i antitrypsin (both measured by nephelometry), /32m (by RJA)
and total proteins were monitored hourly during HD and 2 and 8 hours
after HD during 9 consecutive dialyses (3 cycles of 3 HD each,
alternatively utilizing AN69 or cuprophane membranes in a cross-over
design). All dialyses were 4 hours with bicarbonate dialysate. A2m
significantly increased from hour 3 and peaked 2 hours post-HD (+ 11%
and +9% with AN69 and cuprophane, respectively; P < 0.001 by paired
t-test). Total proteins peaked at hour 4 (+4% and +3%; P < 0.01) and
decreased after HD. f32m significantly decreased during AN69 HD
(—29%; P < 0.001) and remained unchanged during cuprophane HD
(+3%; P = s). In conclusion, HD induces an increases in serum levels
of A2m regardless of the membrane used. We postulate that these
findings are of relevance for HDAA pathogenesis since A2m, previously
identified in HDAA deposits, is closely related to the acute phase
reaction proteins and could represent a new manifestation of an
inflammatory response to the dialysis procedure.
Comparison of intermittent intravenous (i.v.) versus oral (P0) calcitriol
for the treatment of secondary hyperparathyroidism in hemodialysis (HD)
patients. E.R. Fischer and D.C.H. Harris, Department of Renal Med-
icine, Westmead Hospital, NSW, Australia. Both intermittent i.v. and
intermittent P0 calcitriol have been shown to be effective in the
treatment of secondary hyperparathyroidism in HD patients, and it has
been claimed that i.v. calcitriol causes less hypercalcemia. However,
there has been no systematic comparison of the two routes of admin-
istration. Therefore, in a crossover study, 11(9 male) patients (age 45.5
5.5 5EM) on maintenance HD were randomized to receive i.v.
followed by P0 calcitriol for 4 months each, or P0 followed i.v.
calcitriol, commencing at 2 g post-dialysis. Calcium-containing phos-
phate binders were not used. Calcitriol was ceased if hypercalcemia
developed and restarted at 2 or I zg when calcium returned to normal.
Hypercalcemia was frequent—li episodes in 8 patients on i.v. cal-
citriol, and 10 in 7 patients in P0. Dose reduction to I j.g was necessary
in 6 patients on i.v. and the same 6 patients on P0. Serum immunore-
active parathyroid hormone (normal <65 pg/mI) fell similarly after 12
weeks of iv. (406 119 to 301 89 pg/mi) or P0 (306 57 to 240
57, P = 0.04) calcitriol. Parathyroid enlargement was seen in 4 patients
on ultrasound; no size reduction was demonstrated after the first 4
months. Similarly, there was no reduction in activity on quantitative
metabolic bone scan in either group after 4 months. In summary,
intermittent oral calcitriol and intermittent intravenous calcitriol are
equally effective in reducing serum parathyroid hormone, and at a dose
of 2 g postdialysis cause hypercalcemia with equal frequency.
Echocardiographic assessment of cardiac effects of erythropoietin in
hemodialysis patients. K.L. Lynn, AL. Buttimore, J.A. Inkster, D.
Divakar, A.L. Mylius, H. Ikram, B.!. Shand, R.R. Bailey, R. Robson,
and J.E. Wells, Departments of Nephrology and Cardiology, Christ-
church Hospital and Christchurch School of Medicine, Christchurch,
New Zealand. The effects of erythropoietin (EPO) on cardiac function
were studied over 12 weeks. Twenty home hemodialysis patients were
randomly allocated to either EPO 50 U/kg or placebo i.v. three times
weekly. No patients were on antihypertensive drugs. 2-D guided
M-mode echocardiograms were performed at baseline and 12 weeks.
Hemoglobin (P < 0.001) and high shear rate blood viscosity (P = 0.006)
increased on EPO. Blood pressure did not change. Sixteen (8 EPO)
patients had complete echocardiographic data.
Variable"
Adjusted meansa duff
ANCOVAPlacebo EPO (EP)
Ejection fraction % 64.8 75.4 10.6 0.05
Index fract short % 36.2 45.3 9.1 0.05
Heart rate b/mm 66.5 61.9 —4.6 0.07
Myocardial thick mm 14.2 12.2 —2.0 0.15
LV mass g 358 275 —83 0.24
Latrialdiammm 36.2 32.4 —3.8 0.15
a Prestudy value used as covariate
b LV dimensions did not change significantly
EPO therapy for 12 weeks resulted in improvement in myocardial
function and an encouraging, but non-significant, reduction in cardiac
mass.
Long-term effect of low calcium dialysate on parathyroid activity in
dialysis patients treated with calcium carbonate as a phosphate binder.
W.E. James, C. Doecke, G. Allen, M. Cochran, and L. Barratt,
Department of Medicine, Renal Unit, Flinders Medical Centre, SA,
Australia. It has been suggested that long-term low calcium dialysate
bath (L.C.D.B.) use may contribute to renal hyperparathyroidism. We
reviewed the results of 49 hemodialysis patients at Flinders Medical
Centre (F.M.C.) between November 1988 and July 1991 to assess
whether L.C .D. B. was provoking hyperparathyroidism. Twenty-nine
patients were excluded due to complicating illness or alteration of their
regimen. Of the remaining 20 patients, 13 received a L.C.D.B. (defined
as a calcium dialysate bath  1.2 mmol/liter) and 7 patients received a
normal calcium dialysate bath (N.C.D.B., bath l.4 mmol/liter). The
percentage change of parathyroid hormone over the period of review
was +4.9% in the L.C.D.B. group and +0.4% in the N.C.D.B. group;
these results were not significantly different. There was a significant rise
(P < 0.05) in the serum alkaline phosphatase level in both groups during
the period of review, L.C.D.B. +63%, and N.C.D.B. +37%. There was
a significant difference between the mean predialysis phosphate in the
L.C.D.B. group (1.84 mmol/Iiter) and the N.C.D.B. group (1.55 mmol/
liter), P < 0.01. Predialysis hypercalcemia (corrected calcium 2.75
mmol/liter) occurred in 12.6% of the L.C.D.B. group, which was
significantly different to the N.C.D.B. group (5.9%), P < 0.005. A
L.C.D.B. and the use of calcium carbonate as a phosphate binder does
not worsen existing parathyroid activity, is associated with acceptable
control of interdialytic hyperphosphatemia, and increases the risk of
predialysis hypercalcemia. Both groups were associated with a signifi-
cant rise in sALP over the period of review despite stable parathyroid
over-activity.
Effect of essential fatty acid deficiency (EFAD) on renal allograft and
xenograft survival. A.J.F. d'Apice, S. Kalina, A. McKenzie, M. Poli-
hronis, P. Eadie, B. Pollock, A.J. Sinclair, M.J. Pearse, and B.McC.
O'Brien, Departments of Nephrology and Clinical Immunology and
Microsurgery Research Centre, St. Vincent's Hospital, Fitzroy, Aus-
tralia. In 1988, Schreiner et al (Science 240:1032) reported that kidneys
from EFAD Lewis rats were profoundly depleted of glomerular and
interstitial cells which bore Ia and macrophage antigens. When trans-
planted to untreated BN rats, these kidneys survived indefinitely. This
observation was widely interpreted as confirmation of the importance of
passenger leukocytes or dendritic cells in the induction of the allogeneic
response and potentially of clinical importance in prevention of Xe-
nograft rejection. This study was undertaken to confirm the primary
observation. Lewis rats and Balb/c mice were weaned at 21 days and
placed on either an EFAD diet (EFAD# 1) or a normal diet. A further
group of Lewis rats was placed on a more stringent EFAD diet
(EFAD#2). Donors were aged between 2 and 3 months at the time of
transplant. Recipient DA rats were fed normal diets and were aged 2 to
3 months at transplantation. The donors' left kidney was used for
transplantation and the right kidney and liver were used for lipid
analysis and immunohistology. Interstitial macrophages were enumer-
ated using anti-Ia monoclonal antibodies by the peroxidase anti-preox-
idase technique. Lipid analysis was performed on chloroform-methanol
extracted tissues by capillary gas liquid chromatography.
Group
(Donor/diet/recip) N
IA (+) cells
/10 HPF
w9/w6
ratio
Graft survival
(mean SD)
Le/EFAD#l — Le S ND 2.2 0.4 >90 days
Le/control—* DA 9 13.5 2.9 0.06 0.06 8.4 2.4
Le/EFAD#1 —* DA 7 ND 1.7 0.6 6.3 1.1
Le/EFAD#2 — DA 7 22.8 3.6 2.4 1.2 5.9 1.2
Induction of marked EFAD, did not reduce interstitial Ia (+) cells and
there was no prolongation of graft survival of EFAD donor kidneys.
Similar results were obtained with mouse to rat renal xenografts.
Glomerular (GP) and tubular proteinuria (TP) as markers of renal
deterioration in analgesic (AN) and reflux nephropathy (RN). R.S.
Nanra, Nephrology Unit, John Hunter Hospital, Newcastle, NSW,
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Australia. To evaluate the effect of GP and TP on renal function, urine
albumin excretion (UAIbV mg/mmol Cr) and /32-microglobulin excretion(U,mV gImmol Cr) were measured in 52 AN (age 61 9 years, Ccr
4—64, median 38) and 25 RN (age 40 15 years, Cr 10—88, median 55)
patients. In AN patients, total proteinuria (N = 40) was 0.03—4.39 g/day
(median 2.2), UA!bV (N = 50) was 1—1,738 (median 652), and U132mV (N
= 52) was 13—23,773 (median 9,712); the correlation coefficient "r" for
Cr vs. U,bV was 0, and for Cr vs. U m was —0.53 (P = 0.0005). In
RN patients, total proteinuria (N = 22) was 0.02—9.44 g/day (median
4.11), UAIbV (N = 25) was 1—210 (median 110), and Up2mV (N = 25) was
15—6,482 (median 2,749); "r" for Cc,. vs. UAIbV was —0.53 (P = 0.006),
and for Ce,. vs. UmV was —0.52 (P = 0.008). Of 37 AN patients
followed for 12—192 months, 20 had stable and 17 had declining Ccr.
UAIbV in the stable group (1—1,738, median 30) and deteriorating group(2—402, median 65) were similar (P = 0.15), but U02mV in the stable
group (23—10,217, median 131) was less than in the deteriorating group
(range 44—8,835, median 3,339) (P = 0.081). Of 25 RN patients followed
for 12—168 months, 16 had stable and 9 had declining Ce,.. UAIbV in the
stable group (1—208, median 38) and deteriorating group (4—210, median
68) were similar (P = 0.18), but U02mV in the stable group (15—4,800,
median 36) was less than in the deteriorating group (63—6482, median
484) (P = 0.053). These data suggest that in AN and RN, increase in TP
but not GP is a predictor of renal deterioration. C. = creatinine
clearance mI/mm/i .73 m2 surface area, data are Mean standard
deviation.
Risk factors for renal and pelvic cancer. Margaret McCredie, andJ.H.
Stewart, Cancer Epidemiology Unit, NSW Cancer Council; and Renal
Medicine, Westmead Hospital, NSW, Australia. A population-based
case-control study of renal cell carcinoma (RCC) and renal pelvic
carcinoma (TCC) has been undertaken in NSW, 10 years after com-
pound analgesics were banned from sale over-the-counter. A standard
questionnaire seeking information on medical history and consumption
of prescribed drugs, analgesics and tobacco was used in interviews with
cases of RCC (N = 503) and TCC (N 149) diagnosed in 1989—90 and
535 controls from a proportional random sample of the electoral rolls.
Analgesic use was evaluated in four mutually exclusive categories—
aspirin and paracetamol (each as single drugs), aspirin/phenacetin
compounds and aspirin/paracetamol compounds. Risk ratios (RR) were
estimated by multivariate logistic regression. Significant risk factors
and their RR (each adjusted for the effect of all other significant factors)
were:
RCC TCC
Ex-smokers 1.5 1.2
Current smokers 2.3 4.3
Body mass index—highest tertile 1.7 —
Diet pills 1.8 —
Hypertension before 1970 1.9 —
Beta-blockers 1.5 2.1
Kidney injury 4.0 3.8
Kidney infection — 1.8
Lower urinary infection 0.6 —
Phenacetin compounds — 8.1
An increasing risk with increasing use was found for phenacetin-
containing compounds (TCC only) and smoking (RCC, TCC). No
significantly increased risk was found for kidney stones, aspirin/parac-
etamol compounds, aspirin or paracetamol.
The pattern of renal reserve (RR) in renal diseases. R.S. Nanra, S.K.
Nanra, and A.H.B. Gillies, Nephrology Unit, John Hunter Hospital,
Newcastle, NSW, Australia, To evaluate the pattern of RR in renal
diseases, a pilot study was performed in 61 subjects (aged 13—72 years,
median 31) with, glomerulonephritis (N = 24), analgesic (AN), reflux
nephropathy (RN) (N = 23), polycystic kidney disease (N = 9),
hypertension (N = 3), and normal (N = 2). RR was measured by the
increase in hydrated Ccr during infusion of a low-sodium amino acid
solution. The other indices which were measured were: 24-hour urea
excretion (UUreaV mmol/mmol Cr) on the day before the RR test, the
mean arterial pressure (MAP mmHg), basal and increase in albumin
excretion (B-UALbV and' UAIbV mg/mmol Cr), and basal and increase
in fi2Microglobulin excretion (B'Up2mV) and Up2m g/mmol Cr). The
basal Ccr was 11 to 147 (median 83.5) and the range of RR was —8 to
+36 (median 4.5). Thirty-nine subjects (mean age 39 16 years) had no
increase in C. (RR —8 to +8), (RR(—), and 22 (mean age 33 15 years)
had an increase in C. (RR >9), (RR(+)). The RR(—) group had more
AN and RN patients (N = 20 vs N = 3, P = 0.031), a lower basal Ccr
(median 75 vs. 102, P = 0.0029), a greater increase in UmV (median
100 vs. —100, P = 0.0002), and a higher UuraV (mean 36.0 13.3 vs.
29.5 9.5, P = 0.051). There were no differences between RR(—) and
RR(+) groups in age, B-UAIbV and' UAIbV, BUJmV, and MAP. These
data suggest that: (I) there may be differences in RR between glomer-
ular and tubulointerstitial diseases, (2) RR maybe influenced by Ce,. and
protein intake, and (3) RR appears to be associated with changes in
proximal tubular handling of f32m. Cr = creatinine clearance mi/mini
1.73 m2 surface area, data are mean standard deviation.
Nephrocalcinosis in pre-term babies. P. Sivakumar, M. Murnane, C.
Rodda, V. Vu, and M. Mclver, Neonatal Intensive Care and Paediatric
Renal Unit, Monash Medical Centre, Clayton, Victoria, Australia.
Nephrocalcinosis is being identified with increasing frequency in pre-
term infants. The etiology, generally considered to be due to frusemide,
is not clear. Neither is the incidence or the long-term consequences in
babies who survive. A preliminary survey of all pre-term infants of less
than 29 weeks gestation admitted to Monash Medical Centre over a 10
month period identified 14 infants in the 38 babies who survived more
than 2 weeks, in whom an ultrasound diagnosis of nephrocalcinosis was
made. The abnormality persisted in 11. All of these babies had chronic
lung disease and the diagnosis of nephrocalcinosis was made at a mean
age of 35 days. Babies received diuretics, chlorothiazide and spirono-
lactone with or without dexamethasone, together with i.v. fluids con-
taining calcium supplements. No correlation between treatment re-
gimes and nephrocalcinosis could be made. The only significant
biochemical difference in babies with persistent nephrocalcinosis was a
low serum phosphate. Hypertension was noted in 6 of the babies and
persists in 2 who have been followed for more than 18 months. Further
study of the pathogenesis of nephrocalcinosis is required. The abnor-
mality is not necessarily benign and these babies need long-term
supervision of B.P., renal function, and phosphate metabolism.
Lupus nephritis in pregnancy. D.K. Packham, 5.5. Lam, K. Nicholls,
K.F. Fairley, and P. Kincaid-Smith, Department of Nephrology, Royal
Melbourne Hospital, Victoria, Australia. Sixty-four pregnancies under-
taken by forty-one women with biopsy-proven lupus nephritis between
1965 and 1991 were analyzed. Of the sixty-five fetuses, 34% were lost
(including therapeutic abortions), 30% were live but premature, and
37% were term. Deterioration in maternal renal function was seen in
19% of pregnancies, but in only one woman (2%) was there irreversible
post-partum. Hypertension was recorded in 44% of pregnancies; it
developed early (<32 weeks gestations) in 28% and was severe (a
diastolic of >110mm Hg) in 13%. Treated hypertension predated 17%
of pregnancies, and in 6% exacerbation occurred during pregnancy.
Nine women (22%) who developed de novo hypertension in pregnancy
had permanent hypertension post-partum. Increased proteinuria was
recorded in 48% of pregnancies and was irreversible postpartum in 5%.
The presence of the circulating lupus anti-coagulant (LAC) was clearly
associated with significantly high fetal loss rate, although the incidence
of maternal complications did not differ significantly between LAC-
positive and LAC-negative mothers.
Pharmacokinetics of rufloxacin in patients with impaired renal func-
tion. G.J. Perry, T.G.K. Mant, P.J. Morrison, S.H. Sacks, and B.P.
imbimbo, Renal and Drug Research Units, UMDS, Guy's Hospital,
London UK and Mediolanum Farmaceutici, Milan, Italy. Rufloxacin is
a new fluoroquinalone characterized by a broad spectrum of activity
against gram-negative and gram-positive serobic bacteria. The pharma-
cokinetics of rufloxacin were investigated in normal subjects and in
patients with various degrees of renal failure after the administration of
a single oral 400 mg dose. The subjects were classified by glomerular
filtration rate (GFR) normalized for body surface area: group 1: GFR of
>80 ml/min/l.73 m2; group 2: GFR of 80 to 31 ml/min/l.73 m2; group 3:
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GFR of 30 to 11 mI/mm/I .73 m; and group 4: GFR of 10 mI/mini! .73
m2. Each group consisted of 6 subjects. Four out of the six patients in
group 4 were on maintenance hemodialysis or peritoneal dialysis.
Rufloxacin plasma and urinary concentrations were determined by
HPLC and bioassay. A two-compartment model applied on HPLC data
was used to calculate rufloxacin pharmacokinetic parameters. Absorp-
tion and distribution of rufloxacin were not affected by the renal status
of subjects. Clearance of the drug from the body was slow and was
influenced by renal function. The elimination half-lives were 28.1 2.5,
33.7 3.2, and 42.4 3.2 in groups 1, 2 and 3, respectively, and did not
increase further in group 4(31.5 5.3 h), probably due to the clearance
effect of dialysis. The 0- to 96-hour cumulative urinary recoveries of
rufloxacin were 33 3, 27 3, 14 2 of the administered dose in
groups 1, 2, 3,4 2% of the administered dose in groups 1, 2, 3 and 4,
respectively. The renal clearances of rufloxacin decreased linearly with
the decrease in GFR (r2 = 0.848, P < 0.001), while the non-renal
clearance did not change significantly between groups. In conclusion,
rufioxacin 400 mg/day provides therapeutic plasma concentrations in
normals and can be given every 48 hours in patients with moderate to
severe renal impairment.
Lupus nephritis in children and adolescents. AM. Walker, D.J. Lewis,
M. Mclver, and N.M. Thomson, Department of Paediatric Nephrol-
ogy, Monash Medical Centre, Clayton, Victoria, Australia. SLE is
uncommon in childhood, but when compared in adults lupus nephritis is
thought to be more common and more severe. We have reviewed 33
patients with SLE below the age of 25 years at the time of diagnosis
presenting in a 16 year period 1975—91, 28 of whom had evidence of
renal involvement. The mean age at presentation was 15.7 years (range
5—24 years). The female to male ratio was 15:1 and included both pre-
and post-pubertal patients. All patients filled the A.R.A. criteria for
SLE. Mean duration of follow-up was 6.8 years (range 0.1—29 years).
Thirteen patients presented with acute disease (serositis 3; nephrotic
syndrome 3; fever and severe arthritis 2; vasculitis 2; pulmonary
embolus, acute psychosis and thrombocytopenia I each) while 5 had
sub-acute disease (weeks to 2 months) and 15 had chronic symptoms.
Twenty-eight patients (84%) had evidence of SLE nephritis at some
stage during their illnesses; they all had proteinuria and/or hematuria,
and 3 had abnormal renal function at presentation. Renal biopsy was
performed in 26 patients, these all showed lupus glomerulonephritis:
WHO Class II, 3; Class III, 2; Class IV (diffuse proliferative), 14; Class
V (membranous), 4; and advanced sclerosis 3. Treatment included
steroids (31), azathioprine (13), and cyclophosphamide was used in 6(5
diffuse proliferative and I membranous). All patients with Class JIb or
III GN have retained normal renal function; however, of the 20 patients
with more severe pathology, 3 have serum cr >200 tmoliliter, and 5
have developed ESRF, 3 of whom have died (sepsis).
End-stage renal failure (ESRF) therapy in remote areas for western
Australian aborigines: 1988—1991. M.A.B. Thomas, G. Thatcher, R.
Offer, K. Warr, and P. Lee, Renal Unit, Royal Perth Hospital, Perth,
WA, Australia. Australian aborigines from the North-West of WA
(1500—2000 km from Perth) have a  10 fold incidence of predominantly
diabetic and GN end-stage renal failure vs. caucasians; relocation for
urban dialysis often produces cultural isolation, depression and non-
compliance. Following increasing referrals in 1988, and after consulta-
tion with aboriginal groups, local and community health staff with the
WA Health Department began a pilot program of (in order of prefer-
ence) live-related renal transplants, self-care hemodialysis, CAPD or
hospital-based IPD (20 liters via multiprong lines over 12 to 18 hours
thrice weekly). Monitoring was via local medical officers, with
3-monthly reviews in either Perth or their homes. Of 27 referrals from
1988 to 1991 for ESRF therapy, 4 declined after informed discussion,
and 3 relocated to Perth long-term. For 6 LRD Tx, 15 potential donors
were excluded by renal disease, medical unfitness, positive cross-match
or secondary refusal. Three LRD Tx have died (from non-compliance,
infection, amyloidosis), and 3 have stable function (1 recurrent diabetic
nephropathy, 1 HTLV1 transmission). 1 cadaveric TX has stable
function. Four patients are on self-care HD, with machines located in
the home or local hospital for acceptable facilities. Four patients are on
CAPD, with peritonitis episodes every 0 to 5 months. IPD in 5 patients
produced progressive ultrafiltration failure in 4 (1 now on 5 times
weekly IPD, I on Perth HD, 2 deaths from withdrawal from treatment),
and one rehabilitation transferred to self-care CAPD. Results of all
modalities of ESRF management for remote area aboriginals are poorer
than for urban caucasian populations, but offer an alternative therapy to
patients who would choose to withdraw from treatment rather than
relocate for urban dialysis. Survival may be better with dialysis than
transplantation in this remote environment.
Pharmacokinetics of intravenously and orally administered lomefloxa-
ciii in acute pyelonephritis. R.A. Robson, R.R. Bailey, K.L. Lynn, N.
Hay, G. Pidgeon, Department of Nephrology, Christchurch Hospital,
Christchurch, New Zealand. Lomefloxacin is a new, once a day, oral
fluoroquinolone with excellent antibacterial efficacy against urinary
tract pathogens. An intravenous (i.v.) formulation has been developed
recently for the treatment of serious infections. The pharmacokinetics
of i.v. and orally (P0) administered lomefloxacin were investigated in
patients with acute pyelonephritis. Thirteen patients (12 females) aged
18 to 43 years were enrolled. Each received 400 mg lomefioxacin daily
as a single i.v. infusion (30 mm) for 3 days and then orally for 4 to 7
days. The pharmacokinetics were evaluated on the last i.v. and first P0
day (days 3 and 4). Lomefloxacin was measured in plasma and urine by
an HPLC method. Standard methods were used to derive the pharma-
cokinetic variables (mean SD) maximum plasma concentrations
(C), area under the plasma concentration-time curve (AUCO), total
clearance (CL1,) and absolute bioavailability (F).
Cmax AUC CL F
iv. 9.0 2.7 33.4 5.5 204.6 32.5 —
P0 5.5 1.8 32.4 5.7 211.2 34.8 0.97
The study had sufficient power to detect a 10% difference in measured
parameters. In summary, pharmacokinetics of i.v. and P0 administered
lomefloxacin were unaltered by acute pyelonephritis and were similar to
published values in healthy volunteers.
Precision of true creatinine clearance and excretion in 1238 patients and
normals with short collection periods. A.Z. Gyory and M. Ross, Depart-
ment of Medicine, Sydney University, and Renal Medicine, Royal
North Shore Hospital, St. Leonards, NSW, Australia. A rapid, repro-
ducible and practical technique of measuring GFR in clinical practice is
still not readily available. We regularly measure 2 or 3 true creatinine
clearances (Ccr) under water restricted conditions with collection
periods of 104 to 201 minutes and volumes of 101 to 201 ml. Cr were
116 43 1.2, 111 41 1.2, and 110 38 l.6(M SE) for the
first, second (N = 1238) and third (N = 570) periods. Precession from
these duplicate measurements was 18%. Cr for males can be estimated
from the formula:
(227 — Age)Wt
Ccr l4l6XPcr
(Age in years, wt. in kg and "Cr in mmol/liter.) For females this has to
be multiplied by 0.85. Creatinine excretion (mmol/day) was remarkably
constant in 118 patients who had up to 9 repeat estimations (interval 3
days to 12 years) average CV was 11.5% for intra-patient variation.
Normal (N = 71) Cr (mI/rn/i .73 m2) was 12 27 3.2 and varied with
age. C. as a percent corrected for age can be obtained from formula:
106 x GFR/SA
166 — Age
Short collection periods without water loading offer a very suitable and
reproducible way of rapidly measuring C. if performed by trained
nursing staff.
Membranous nephropathy: Prospective study of 51 patients. N.M.
Hay, R.R. Bailey, K.L. Lynn, and R.A. Robson, Department of
Nephrology, Christchurch Hospital, Christchurch, New Zealand. The
outcome of 51 patients (33 males; mean age 50.8 17.7, SD yr; 49
Caucasian, 2 Maori), aged 14 years and over with biopsy-proven
membranous nephropathy (MN) was studied prospectively. The pa-
tients were enrolled between July 1, 1972 and June 30, 1991. Patients
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with SLE were excluded. MN was secondary to drug therapy in 8 (gold
3, NSAID 3, penicillamine I, captopril 1). All patients were HBsAg
negative. In the majority of cases these patients did not receive
immunosuppressive therapy. Forty-seven (92%) presented with the
nephrotic syndrome, 8 (16%) with a plasma creatinine 0. 15 mmol/liter
and 28 (55%) had hypertension (BP > 150/90 mm Hg or on therapy).
Mean follow-up was 5.5 years (range 4 months to 19 years). The 10-year
cumulative renal survival was 78% and overall survival 66%. Six
patients have entered the renal replacement program, and 6 have died of
non-renal causes. Of the remaining 39, 8 have renal insufficiency, 27
hypertension and 22 proteinuria. Complete remission occurred in 17
(33%)—l 1 spontaneously, 4 following withdrawal of the offending drug,
and 2 after immunosuppressive therapy. Poor prognostic indicators at
presentation included renal insufficiency, need for antihypertensive
therapy, pathological stage IV on renal biopsy and older age. MN is an
indolent disease with a good chance of spontaneous remission. Aggres-
sive treatment in most patients appears to be unwarranted.
A novel manifestation of aluminium toxicity: Prurigo nodularis. M.A.
Brown, C.R.P. George, S. Kalowski, R.A. Evans, and A.B. Corrigan,
Concord Hospital, NSW, Australia. We have observed three mainte-
nance hemodialysis patients in whom aluminium overload has been
associated with prurigo nodularis (PN). PN is characterized by chronic
pruntis and widespread nodular skin lesions occurring mainly on the
trunk. In two patients the rash developed after 8 months of hemodial-
ysis, and in the third 10 months after recommencement of hemodialysis
following failure of a renal transplant. In all three, the presence of
aluminium-associated osteomalacia was demonstrated on bone biopsy.
Apart from uremia, none had evidence of any other condition which has
previously been causally associated with PN (such as insect bites,
venom stings, or coeliac disease). Although treatment with oral and
topical antibiotics, tricyclic anti-depressants, topical and intralesional
corticosteroids produced little or no response; the itch in all patients
responded to courses of desferrioxamine within one month, and the
nodular lesions on the skin shortly thereafter. It is suggested that PN
may be a manifestation of aluminium toxicity.
Normal values for overnight urinary albumin excretion (UAE) in
healthy schoolchildren. P. Henning, R. Ryall, S. Harris, and J. Penfold,
Departments of Nephrology, Chemical Pathology and Endocrinology,
Adelaide Children's Hospital, SA, Australia. Elevated rates of UAE
appear to predict diabetic nephropathy in adults, although the actual
"pathological" cut-off has been derived retrospectively. In children the
UAE rate may exceed control values yet not reach this predictive level
for nephropathy. In addition, age-related normal data are needed in
children. We measured UAE in a single overnight urine sample ob-
tained from 888 children aged 5 to 17 years (420 females, 468 males).
Albumin concentration was measured using an immuno-turbidometric
method, and creatinine concentration using the standard Jaffe reaction.
UAE was expressed as an excretion rate and as an alb/creat ratio, and
analyzed as log transformed data. Each yearly age group was compared
to every other using a t test. This analysis revealed a significant increase
in UAE at 9 to 10 years, which was not seen at any other age. Female
values were higher than male values up to this age.
UAE rate (median)
p.g/min
95% Confidence
limits
Female 9 years (N = 257) 2.07 0.5—8.6
Male 9 years (N = 240) 1.92 0.4-7.2
All subjects 10—17 years 2.96 0.6—13.9(N = 391)
When expressed as an alb/creat ratio UAE did not increase. The
proportionate increase in albumin and creatinine excretion at 10 years
of age correlates with the normal increase in BP in healthy children and
may reflect the onset of adrenarche.
Ultrasonography (US) and computed tomography (CT) in the diagnosis
of analgesic nephropathy. M. Segasothy, S.A. Samad, A. Zulfigar, S.P.
Menon, Z. Morad, and W. Shaariah, Departments of Medicine and
Radiology, Universiti Kebangsaan Malaysia, Department of Nephrol-
ogy, General Hospital, Kuala Lumpur, Malaysia. The value of US in
the diagnosis of renal papillary necrosis (RPN) in patients with impaired
renal function has been established (Weber et al: Nephron 39:216—222,
1985). However, the role of CT in the diagnosis of RPN has not been
well studied. In order to determine the value of CT in the diagnosis of
RPN, we performed US and CT in patients who had consumed
excessive quantities of analgesics (>1 kg) with normal or impaired renal
function (serum creatinine ranging from 75 to 1094 rmol/liter). Criteria
for the diagnosis of RPN by US and CT was renal papillary calcifica-
tions. As negative controls, 10 patients who had renal impairment due
to glomerulonephritis but who had no history of analgesic abuse were
studied. RPN was documented in 20 out of 40 patients by US and in 14
out of 40 patients by CT. In 11 patients both US and CT were positive.
In 9 patients US was positive while CT was negative. In 3 patients CT
was positive while US was negative. RPN was not documented in 17
patients and in any of the negative controls either by US or by CT.
Prevalence of RPN was 50% using US and 35% using CT among
analgesic abusers. Using US as a gold standard, sensitivity of CT was
55%, specificity of CT was 85%, positive predictive value was 78.6%,
and negative predictive value was 34.6%. Percent agreement with CT
and US was 70%. Cohen's Kappa statistic adjusting for chance agree-
ment was 40%. Based on these results it is found that US yielded a
higher percentage of positive cases of RPN. We recommend that in
patients who have abused analgesics and who have impaired renal
function, US is the investigation of choice for the diagnosis of analgesic
nephropathy. CT could be performed when US is negative.
Thrombocytopenia in continuous hemodiafiltration (HDF) in intensive
care acute renal failure (ICU ARF): 1988 to 1991. K.J. Warr, G. Leslie,
1G. Jacobs, M. Webb, M.A.B. Thomas, P. Lee, and K. Y. Lee,
Departments of Intensive Care, Renal Medicine and Haematology,
Royal Perth Hospital, Perth, WA, Australia. To determine the preva-
lence and associations of thrombocytopenia in ICU ARF treated with
HDF, 144 consecutive cases were prospectively analyzed for daily
platelet count (x 109/liter), ICU admission diagnosis, disease severity(admission APACHE II score), heparin dose, effectiveness of HDF
(Day 1 minus Day 4 creatinine, ultrafiltration volume), survival, and
compared to 150 ICU non-ARF admissions, untreated by continuous
heparin. Mild transient thrombocytopenia was consistently observed in
the ARF group as a whole from commencement of HDF [Day I = 134
(107—207), median (quartiles), nadir at Day 4 = 103 (62—160), P =
.0003,
Wilcoxonj returning to baseline by Day 9 without specific therapy; no
significant change in platelet count was seen in ICU non-ARF admis-
sions. Multivariate analysis identified admission APACHE II score,
trauma, post-cardiac bypass patients, and serum lactate (but not fall in
creatinine, ultrafiltration volume) as independent determinants of plate-
let count. 5.8% of patients had platelet count <50 at start of HDF,
which improved by day 2 to 50 to 150, without a transient secondary
decline at Day 4. Only 2 cases of heparin-associated thrombocytopenia,
confirmed by positive agglutination, were detected. Severe thrombocy-
topenia was managed by avoidance of heparin, pre-filter dilution,
increased blood flow prostacyclin; low molecular weight heparin did
not apparently alter rate of platelet recovery. Thrombocytopenia in
HDF for ICU ARF is common, multifactorial, usually mild, maximal at
Day 4 of HDF, and self-limited, without requirement for specific
therapy. Patients with trauma, cardiac bypass and severe acidosis are at
particular risk for this complication.
A comparison of laboratory and clinical factors in patients treated with
hemodialysis (HD) and subsequent long-term hemodiafiltration (HEW).
PG. Kerr, A. Argues, B. Canaud, J.L. Flavier, and C. Mion, Depart-
ment of Nephrology, Lapeyronie University Hospital, Montpellier,
France. Hemodiafiltration is purported to provide better cardiovascular
stability for dialysis patients; other possible benefits of this therapy
have not been well defined. We have compared serial treatment with
HD and HDF in 20 stable patients over a period of 18 months. Dialysis
parameters were: dialysate composition and flow, duration, and mem-
brane used (polysulfone) were the same in the two periods except for
the added convection of HDF (18—20 liters/session) and a higher
tolerated blood flow in HDF (369 24 vs. 348 33 mI/mm, P < 0.005).
For both modes, ultrapure, sterile bicarbonate dialysate was used, and
for HDF this was further ultrafiltered for use as infusate. Clinical
parameters (pre- and post-dialysis BP, dry weight and weight loss per
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session) were remarkably similar in the two treatment periods, indicat-
ing that stable patients do not benefit further from this therapy in terms
of these factors. The clearance of urea was significantly improved with
HDF, which was reflected in a higher Kt/V (1.55 0.07 vs. 1.41 0.05,
P < 0.001) and lower TACOra (16.3 1.0 vs. 19.3 1.0 mmol/liter, P
< 0.0001) without a significant change in the PCR. The clearance of
beta-2 microglobulin (132m) was also significantly improved by HDF
compared to HD (% reduction in 132n1: 62.7% in HDF vs. 54.8% in HD,
P < 0.05). There was a small difference in in-patient days favoring HDF
which was of arguable significance. A cost analysis revealed no
difference between HD and HDF (excluding initial capital costs), the
cost of infusate production being offset by greater reuse of dialyzers.
Thus, the benefit of HDF in stable dialysis patients is the improved
clearance of small molecules and beta-2 microglobulin without increas-
ing dialysis time. Further clinical benefits due to the iniproved clearance
may only become apparent with longer follow-up.
Whole blood serotonin levels are markedly elevated in patients on
dialytic therapy. P.G. Kerr, A. Argues, C.M. Mion, Department of
Nephrology, Lapeyronie University Hospital, Mon tpellier, France. The
normal range for whole blood serotonin levels in CRF patients has not
been defined. As serotonin may be implicated in platelet abnormalities,
hypo- and hypertension and itch in dialysis patients, serotonin whole
blood levels were measured in a group of patients with chronic renal
failure. The levels were elevated in 12 patients with moderate (mean
serum creatinine 335 54 mol/liter) chronic renal failure (270 46
/.Lg/liter) compared to II normals (163 17 gIliter P < 0.05; quoted
normal range <300 pg/liter) but did not correlate with serum creatinine
levels. There was a marked elevation in serotonin levels in dialyzed
patients, including in hemodialysis (polysulfone, N = 6, 747 234
pg/liter and cuprophane membranes, N = 6, 708 198 pg/liter),
hemodiafiltration (N = 12, 695 130 pg/liter), and especially peritoneal
dialysis (N = 6, 1148 162 pg/liter). All results were significant (P <
0.01) compared to normals and compared to the non-dialyzed group (P
<0.05). The level of serotonin decreased during hemodialysis regard-
less of the membrane used. There was no correlation of serotonin levels
with pruritus or hypertension, although there was a negative correlation
with diastolic blood pressure. The reference range for serotonin whole
blood levels needs to be broadened when considering dialyzed patients.
Beta.2 microglobulin (132m) removal in hemodiafiltration (HDF) after
reprocessing dialyzers with peroxyacetic acid. P.G. Kerr, A. Argues, B.
Canaud, J.L. Flavier, C. Mion, Department of Nephrology, Lapey-
ronie University Hospital, Montpellier, France. Reuse is widely prac-
ticed though its effects on the efficacy of removal of solutes and more
recently proteins such as /32m are the subject of much debate. There is
evidence to suggest that reprocessing with formalin, and/or bleach,
maintains dialyzer performance. This study examines peroxyacetic acid
use as the cleansing/sterilizing agent using Renatron machines. It has
been claimed that peroxyacetic acid does not remove any secondary
membrane that may have formed, thus 132m removal may be subse-
quently impaired. We analyzed reuse in 24 patients using polysulfone
membranes in a HDF unit over a two year period. The mean maximum
number of uses achieved was 20.1 0.5. Several factors considered
cinically to influence the number of reuses achievable (Hb, WCC and
platelet levels, ESR and fibrinogen and total protein level) were found
not to affect the maximum number of uses obtainable. We then assessed
prospectively the performance of 26 polysulfone dialyzers after peroxy-
acetic acid reprocessing up to 20 times, particularly with regard to their
ability to remove 2m. The percent reduction in serum /32m was 71.8
1.1% on first use, 72.7 1.3% on 2nd, and 66.8 2.2% on 20th use (P
<0.05 by paired t-test). On all occasions, the percent reduction in f32m
exceeded that of urea (for example, 1st use % reduction in urea 69.9
1.1%; 20th use 66.3 2.4%). In addition we measured the % reduction
in retinol binding protein (MW 21,000) and found it to be moderately
reduced by the 20th use (11.2 2.4% vs. 18.6 2.1%,P<0.05). Thus,
we can report that polysulfone membranes reprocessed with peroxy-
acetic acid used for HDF up to 20 times exhibit maintained high level
removal of compounds beyond a MW of 12,000. Any secondary
nembrane formation that occurs appears not to influence the subse-
quent removal of /32m. Thus we would recommend the use of peroxy-
acetic acid for reprocessing dialyzers in a safe and efficacious manner.
The accuracy of Kt/V estimations in hemodiaflltration (HDF) using
percent reduction in urea (PRU): Incorporation of urea rebound. P.G.
Kerr, A. Argiles, B. Canaud, J.L. Flavier, C. Mion, Department of
Nephrology, Lapeyronie University Hospital, Montpellier, France. The
estimation of Kt/V by utilization of the pre- and post-dialysis urea levels
[PRU and In(Upr/Upost)1 provides a simple, quick technique that can be
applied at the bedside. However, the accuracy of such techniques has
been questioned. One possible reason for this inaccuracy may be the
post-dialysis rebound in serum urea levels that is frequently observed.
We assessed the urea rebound at 30 minutes post-dialysis in 34
hemodiafiltered patients and compared the calculation of Kt/V using
this urea level with that using the immediate post-dialysis level. The
results obtained using 2 formulae incorporating PRU and also the
In(Upre/Upost) were then compared to the Kt/V calculated by urea
kinetic modelling (UKM), also utilizing both serum urea levels. The
degree of urea rebound observed was large, 21.4%, as was the creati-
nine rebound, 26.0%, being a reflection of the short duration, rapid flux
dialysis. The formulae for calculation of Kt/V all significantly correlated
with Kt/V by UKM (r values 0.799—0.959, all P < 0.0001) but all gave
results significantly different to Kt/V by UKM (P < 0.001 by paired
t-test). The formula of Jindal (0.O4PRU- 1.2) overestimated Kt/V by 0.19
0.03 or 0.16 0.01 for immediate or delayed urea sampling,
respectively; whereas that of Basile (0.O23PRU-0.284) underestimated
by 0.14 0.03 or 0.07 0.02. The loge formula underestimated Kt/V by
a greater degree. In all cases the delayed urea sampling provided
estimated Kt/V values closer to the UKM derived Kt/V values. For
assessment of Kt/V by these formulae, or by UKM utilizing single pool
kinetics, the urea rebound is too large to ignore in the setting of short
duration, rapid flux dialysis.
Age and parathyroid (P'FH) suppression on dialysis. A. St. John, K.
Hoad, P. Lee, K.J. Warr, M.A.B. Thomas, Departments of Biochem-
istry and Renal Medicine, Royal Perth Hospital, Perth WA, Australia.
To examine determinants of PTH concentrations in non-parathyroidec-
tomized patients on maintenance dialysis, data on calcium-phosphate
metabolism, dialysis duration (Dx months) and therapy (including
Ca.C03 g/day) were prospectively recorded six-monthly between 1988
to 1991 in 500 samples from 142 patients. Intact PTH levels by
immunochemiluminometry (N:0.5—5.5 pmol/liter) were  10 pmol/liter
in 73% of samples (median 42, range 0.6—305), whereas alkaline
phosphatase (N:40—135 U/liter) was elevated in only 25% of samples
(98,0—890 U/liter). Patients with 3 measurements of PTH were divided
into: (I) High: PTH #1 >10 pM and stable/increasing over time (N =
18); (2) Decreasing: PTH #1 l0 and 50% fall over time, (N = 14),
and (3) Low: median PTH <10 (N = 14).
High Decreasing Low P
PTH #1 67 (23—240) 62 (21—305) 5 (0.7—l6r 0.00 vs. H,D
Age years 51(38—74) 51 (34—67) 67 (19_74)a 0.00 vs. H,D
Dx months 51 (25_203)a 43 (21—162) 45 (26—89) 0.00 vs. D,L
CaCO3 1.7 (0—4.5) 4.5 (l.39)a 1.5 (0.4—9) 0.04 vs. H
By multiple regression, elevated PTH was independently associated
with duration of dialysis (r 0.48, P = 0.006) and serum P04 (r = 0.49,
P = 0.005), the extent of fall in PTH correlated with lower serum urea(r =
—0.31, P = 0.03), and low PTH levels correlated with increasing
age (r = —0.48, P = 0.04). Clinically-indicated bone biopsies demon-
strated pure hyperparathyroidism in 4/4 High patients, mixed HPTH/
osteomalacia in 2/3 Decreasing patients and adynamic bone disease in
2/2 Low patients. Biochemical hypereparathyroidism is very prevalent
with evolution over time on dialysis, affected by P04 control. Relative
"hypoparathyrodism" is a feature of the elderly dialysis patient and
may predispose to adynamic bone disease.
Calcium alginate versus aluminium hydroxide in maintenance hemodi-
alysis D.C.H. Harris, L. Yuill, Department of Renal Medicine, West-
mead Hospital, NSW, Australia. The risk of aluminum toxicity has
stimulated a search for safe alternatives to aluminium-containing phos-
phate binders. In preliminary studies from Germany, calcium alginate,
a natural aluminum-free polyuric acid, has been reported to be an
effective and safe treatment for uremic hyperphosphatemia in dialysis
1046 Abstracts
patients. Treatment with calcium alginate (C, max 8.4 g/day) was
compared to that with aluminium hydroxide (A, max 5.4 g/day) in 17
chronic hemodialysis patients in a 12 month randomized, cross-over
trial. After 5 and 6 months of treatment, serum phosphate was no
different with C compared to A (for example 6 months, 1.75 0.15 vs.
1.68 0.09 mmollliter, SEM). Plasma aluminium was significantly
lower in C from 2 months (1.54 0.26 vs. 3.04 0.62 molIliter, P <
0.01). Plasma aluminum after 40 mg/kg lvi desferrioxamine tended to
be lower in C (for example, 6 months, 4.83 0.68 vs. 8.16 1.48
mol/liter, NS). Serum calcium, magnesium, alkaline phosphatase and
immunoreactive parathyroid hormone were no different during the
treatment periods. For adequate phosphate control, an extra phosphate
binder was required with both C and A (Mylanta II, 1.1 0.3 vs. 0.4
0.3 tablets/day, NS). C was well tolerated, and mild diarrhea and
hypercalcemia in one patient each were the only side effects. Of 12
patients who completed both arms of the study, 5 preferred to take A,
5 preferred C, and 2 had no preference. In summary, calcium alginate is
a safe, well-tolerated and effective phosphate binder, but must be used
with another agent in the majority of patients receiving maintenance
hemodialysis.
Intestinal failure secondary to scierosing peritonitis in patients on
chronic peritoneal dialysis—A role for home TPN? A. Chrysostomou, G.
Becker, R.J.S. Thomas, D.M. Russell, Department of Nephrology and
Clinical Nutrition Service, The Royal Melbourne Hospital, Victoria,
Australia. Sclerosing peritonitis is a recognized major complication
associated with chronic peritoneal dialysis (PD). In advanced cases,
chronic intestinal obstruction results in malnutrition and the need for
TPN. Between 1979 and 1991, 311 patients at The Royal Melbourne
Hospital received chronic PD, and 6 patients, aged 33 to 61 years,
developed sclerosing peritonitis (incidence 1.9%). The median duration
of PD until intestinal failure was 4.5 years (range 1.5—12.5 years). All
had prior episodes of peritonitis with a mean of I infection episode per
10 months of dialysis (range 1/27 months to 1/4.5 months). Five out of
six patients had multiple episodes of peritonitis. Polymicrobial cultures
were obtained from the peritoneal effluent of all patients, although
coagulase negative staphlococcus was the predominant organism. Five
out of six patients have died of intestinal failure (mortality 83%), and I
patient has been on Home TPN for 9 months. The early recognition of
sclerosing peritonitis in patients on chronic peritoneal dialysis is para-
mount to prevent intestinal failure, and a change from PD to hemodi-
alysis is recommended. Home TPN in a patient on hemodialysis is both
a technical and metabolic challenge.
Changes in blood rheology during hemodialysis. B.!. Shand, A.L.
Buttimore, K.L. Lynn, L.J. Chisholm, G.M. Stanley, Department of
Nephrology, Christchurch Hospital, Christchurch, New Zealand. We
investigated the changes in indices of whole blood viscosity in 7 home
hemodialysis (HD) patients during two 5 hour standardized HDs, using
either flat plate or hollow fiber Cuprophan membrane dialyzers. Blood
samples for hematological, viscometric and filtration studies were
collected at baseline, 2 minutes, and then at hourly intervals. HD using
either membrane caused a similar pattern of changes with an increase in
mean hematocrit, whole blood and plasma viscosity, and whole blood
filtration, while red blood cell (RBC) deformability did not change. HD
with a hollow fiber dialyzer was associated with significant and rapid
changes in plasma viscosity (P < 0.02) and whole blood filtration (P <
0.05). Three patients developed marked rheological changes with both
dialyzers. The rise in whole blood and plasma viscosity with either
membrane both correlated with increased hematocrit (r = 0.90and 0.89,
respectively). The cause of the reduction in whole blood filtration is
unknown and occurred independently of the viscosity increases and
was also not the result of impaired RBC deformability. We conclude
that HD may cause significant changes in blood rheology, mainly as a
result of hemoconcentration. In the case of Cuprophan® dialyzers, the
time frame and magnitude of these rheological changes is influenced by
the membrane configuration.
Low dose subcutaneous (s.c.) vs. intravenous (i.v.) recombinant human
erythropoietin (EPO) in maintenance hemodialysis (HD) patients. PG.
Barclay, E.R. Fischer, D.C.H. Harris, Departments of Renal Medicine
and Pharmacy, Westmead Hospital, NSW, Australia. Although s.c.
EPO has been reported to correct anemia in HD patients at lower doses
than iv. EPO, these trials involved high dose EPO and did not control
for the time-related fall in dose, which has been shown with low dose
EPO. Therefore, a double crossover study was performed to determine
the effect of route of administration of EPO on hemoglobin (Hb)
response. EPO dose was kept constant unless Hb rose above 100 g/liter,
when the dose was reduced until Hb was 90 to 100 g/liter. Initial EPO
dose was 77.5 10.7 (mean saM) U/kg/week. Thirteen (4 male) stable
HD patients, who had been on i.v. EPO for 15.3 2.6 months, were
given EPO i.v. for 12 weeks (IVI), then s.c. for 24 weeks and then i.v.
(IVI'2) for a further 24 weeks (as yet IVI#2 has not been completed).
Iron status and other factors known to modify EPO response were kept
constant. Two patients who developed iron deficiency during the study
have been excluded from analysis. The mean Hb (g/liter) during the last
3 months and final Hb of each arm was no different.
Last 3 months
Last 3 months s.c.-IVI Final
IVI'
SC
IVI#2
87.4 2.2
89.4 2.8] NS
86.5 3.3 ] NS
1.3 2.8
2.8 3.0
89.4
88.1
87.6
3.9
3.4
3.8
Mean Hb was higher on i.v. EPO in 6 patients (by 5.5 1.9 g/liter), and
on s.c. EPO in 5 patients (by 10.7 4.2 g/liter), and by >5 g/liter in 3
patients while on i.v. and in 4 while on s.c. EPO. In conclusion,
although there is no overall advantage in administering low dose EPO
subcutaneously or intravenously, the most effective route of adminis-
tration should be determined for each patient.
Comparison of 3 immunosuppressive regimens in cadaver renal trans-
plantation: Long-term cyclosporine (CsA), short-term CsA followed by
azathioprine and prednisolone, and azathioprine and prednisolone with-
out cyclosporine. An 8 year follow-up. Australian Collaborative Trial
Committee. A study comparing the three treatment regimens com-
menced in 1983. 489 patients were entered into the study, as shown in
Table I.
Total Cony. tmt
Long-term
CsA
3 month
CsA then
cony.
489 158 166 165
Dead 3l 17 20
Lost to f/u. 1 2 1
On dialysis 38 42 39
Died with a
functioning
kidney 22 11 14
Alive with no
changeinTmt 89 105 101
a = <o.os
Patients assigned to long-term cyclosporine (GsA) or short-term CsA
had similar 12 month actuarial survival (98.4 vs. 96.4) and graft survival
(83.9 vs. 82.1). Patients assigned to azathioprine and prednisone with
the optional use of ATG had a significantly poorer survival rate of
91.3% (P < 0.05) at 12 months due to increased deaths secondary to
cardiovascular disease. Graft survival did not differ significantly. At 96
months, long-term GsA and short-term GsA showed a 91% and 88%
patient survival, respectively, while conventional therapy patients
continued to have a significantly worse survival (P < 0.05). Graft
survival at 96 months was 66% on long-term CsA, 62% on short-term
CsA and 54% in the conventional arm (P > 0.05). Serum creatinine was
169.1 87 in long-term CsA, 129.65 53 in short-term GsA (P < 0.05)
and 153.4 84 mol/liter in conventional treatment at 96 months. At 96
months, graft survival is not significantly different between the 3 arms
of the study. Patient survival continues to be better in the CsA arms.
CD-25 (anti-IL-2R) monoclonal antibody (mAb) treatment (Rx) de-
pletes IL-2R+ (p55) mononuclear cells (MNC) from cardiac but not
concurrent rat renal allografts. W. Hancock, J. Kupiec-Weglinski, H.
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Ueda, N. Tilney, Departments of Pathology and Immunology, Monash
Medical School, Melbourne, Victoria, Australia, and Surg Res Lab,
Harvard Medical School, Boston, Massachusetts, USA. Clinically,
CD25 mAb Rx of acute renal Tx rejection has proven less satisfactory
than anticipated from rodent studies. CD25 mAb Rx (ART-18, 300
g/kg/d x 10 days, i.v.) was previously shown to deplete IL-2R+ MNC
from rat cardiac allografts (LBNFI—*LEW) but not from kidney grafts.
However, if normal renal function was maintained by omitting native
nephrectomy (Nx), mAb did deplete IL-2R+ MNC, suggesting suppres-
sion of host ADCC by uremia. We now asked whether uremia would
therefore inhibit depletion of LL-2R+ MNC from both heart and kidney
allografts in dual Tx recipients. Accordingly, LEW rats with Nx
received LBNF1 heart and kidney grafts plus CD25 mAb Rx. Control
rats (2—4/group) received single allografts and either no Rx; CD25/no
Nx, CsA 15 mglkg/d x 10 days, or low CsA CD25 mAb x 10 days.
Graft function was assessed by creatinine (Cr) or ventricular contrac-
tions. Rats were sacrificed on day 7 post-Tx for histology or followed
until death. Untreated Nx dual recipients rejected their cardiac grafts at
7 I day and died of uremia at 9 1 day. CD-25 mAb Rx dual
recipients showed excellent cardiac function but were uremic from day
7 and died at 13 2 days. Analysis of intragraft IL-2R+ MNC (% total
leukocytes) at 7 days post-Tx showed:
Cr
mg/dl
Heart
% IL-2R+ Survival
(I) Dual Tx
No Rx 5.8 16.2 1 7 1 days
CD-25 Rx 3.2 0.4 0.3 >l3C
(2) Single Tx
No Rx 5.8 14.6 3.2 7 1
CD-25 Rx 3.2 0.2 0.l 21 2
CD-25/no Nx <1 0.2 o.Ia 21 2
CsA Rx <1 0.1 0.l >60
low dose CsA 2.8 13.6 2.7 7 I
CD25/low CsA 1.7 0.1 O.l >45a
Kidney
% IL-2R+ Survival
(1) Dual Tx
NoRx 17.3±4.2 9±ldays
CD-25 Rx 15.2 5.2 13 2
(2) Single Tx
No Rx 16.6 3.6 10 4
CD-25 Rx 15.1 5.3 23 7C
CD-25/no Nx 0.8 0.6a 23 7C
CsARx 0.2±0.la >60a
low dose CsA 14.4 4.3 16 2
CD25/low CsA 2.3 1.1" >45
a p < 0.001, b p < 0.005, C P < 0.01 cf. to respective no Rx group
These data show that uremia inhibits CD25 mAb depletion of IL-2R+
MNC from rejecting renal but not corresponding cardiac allografts.
Moreover, adding even sub-therapeutic doses of CsA to the CD25 mAb
Rx protocol restores the therapeutic effect of CD25 mAb Rx in renal Tx
recipients and synergistically prolongs graft survival.
Diltiazem in renal transplant recipients receiving cyclosporin A (CsA).
Anastasia Chrysostomou, Rowan Walker, Timothy Mathew, Graeme
Russ, Anthony d'Apice, Pricilla Kincaid-Smith, Royal Melbourne Hos-
pital, Victoria, and The Queen Elizabeth Hospital, South Australia,
Australia. Of 113 CsA treated primary renal allograft recipients, 60
were randomized to receive either standard therapy (ND), and 53
received standard therapy plus diltiazem (D). There was no difference
in CsA blood levels between ND and D at all intervals between 3 and 24
months, yet the D required 35% less CsA than the ND group (measured
at 12 months). At all intervals to 24 months follow-up there was no
difference in blood pressure, renal function as measured by serum
creatinine (mean SD) (ND; 0.12 0.02 mmol/liter, D; 0.10 0.03
mmol/liter at 24 months), or the number of grafts lost in the 2 groups
(ND; 4 lost, D; 3 lost). There was no significant difference in the total
number of rejection episodes in the 2 groups (ND; 89 episodes, D; 71
episodes). However, the severity of rejection episodes was greater in
the ND group as evidenced by a significant difference in the usage of
orthoclone OKT3 (ND; 17 courses OKT3, D; 8 courses OKT3, P <
0.05). Of biopsy proven episodes of rejection there was also signifi-
cantly more episodes of vascular rejection (ND; 14 episodes, D; 3
episodes, P = 0.005). The incidence of primary non-function was less in
the D group (ND; 11 patients, D; 4 patients, P = 0.05). The D group
required 35% less CsA than the ND group, with no change in graft
outcome. Diltiazem with CsA resulted in significantly less severe
rejection episodes and in particular fewer episodes of vascular rejec-
tion.
Lymphocytes from a highly sensitized dialysis patient synthesize a
monoclonal antibody to the HLA-B5 cross-reactive antigen group
(CREG). D.A. Power, B.K. Weber, I. Al Muzairai, M.C. Jones,
Departments of Nephrology and Clinical Immunology, St. Vincent's
Hospital, Fitzroy, Victoria, Australia. Antibodies in sera from highly
sensitized dialysis patients react with T lymphocytes from 50% of
normal donors. Some studies have suggested that this is due to the
presence of antibodies against public HLA specificities (cross-reactive
groups or CREG's). We have produced a human monoclonal antibody
of class IgG1A (called FLP) to HLA antigens of the —B5 CREG by
Epstein-Barr virus transformation and somatic cell hybridization of
lymphocytes from a highly sensitized patient (FW). This antibody was
not cytotoxic, even in AHG-CDC. Assay of FLP against 57 cell lines (29
normal peripheral blood lymphocytes and 28 lymphoblastoid cell lines)
showed a strong correlation between reactivity of FLP by flow cytom-
etry and the presence of members of the HLA-B5 CREG. When
attempting to correlate the specificity of the monoclonal antibody FLP
with the reactivity of serum samples against normal peripheral blood
lymphocytes by flow cytometry, it was apparent that this antibody was
only one of a number present in sera from the patient FW. A rabbit
anti-idiotypic antibody was then raised against FLP; it inhibited binding
of IgG antibodies in serum obtained from FW to cells which reacted
with FLP and, also, binding to a cell which did not. These results
demonstrate that: (1) B-cells from highly sensitized patients produce
antibodies to CREG's, (2) IgG antibodies from these patients may be
non-cytotoxic, and (3) alloantibodies against distinct specificities may
possess similar idiotypes.
T-cell antigen receptor Va gene expression in a rejecting renal al-
lograft. MC. Falk, Y. Zhang, JR. Chapman, L.P. Roy, J.F. Knight,
Renal Research Laboratories, The Children's Hospital, Camperdown
and Renal Unit, Westmead Hospital, Westmead, NSW, Australia.
Rejection of a renal allograft by the host is usually characterized
histologically by the infiltration of mononuclear cells. Histochemical
staining has demonstrated that the infiltrate is predominantly composed
of T-cells. This observation provides the rationale for the use of OKT3,
a pan-T-cell monoclonal antibody directed at CD3, to treat rejection.
The majority of T-cell antigen receptors (TCR) comprise two distinct
glycoproteins, termed a and f3. These molecules have variable (V)
regions analogous to immunoglobulin V regions, which confer antigen
specificity. In humans the gene for the TCR Va chain is located at
chromosome l4ql 1-12. To date, 48 different Va genes have been
described, which have been assigned to 18 families on the basis of
sequence homology. If T-cells mediating rejection belonged to a specific
Va or V/3 family or families, it would be possible to design more specific
strategies directed at those particular cells. To explore this hypothesis,
we have synthesised 5' oligonucleotide primers for each of the 18 TCR
Va families and a 3' primer specific for the Ca (constant region) gene.
Messenger RNA was extracted from peripheral blood mononuclear
cells (PBMC), from a normal" kidney (the unaffected pole of a kidney
removed for Wilms' tumor) and from an allograft undergoing acute
rejection, and converted to cDNA by reverse transcription. The poly-
merase chain reaction was used to detect the presence of TCR Va gene
expression in these samples and to characterize the spectrum of Va
families being expressed. In our preliminary experiments, expression of
17/18 TCR Va genes was demonstrated in PBMC. In the "normal"
kidney several faint bands were seen suggesting the presence of a few
passenger lymphocytes. In the rejecting renal allograft expression of
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15/18 TCR Va genes was readily detected, suggesting that, at least in
this specimen, a polyclonal T-cell infiltrate was occurring. We plan to
use this method to analyse evolution of the T-cell infiltrate during the
process of cellular rejection.
Long-term reduction in bone mineral density following renal transplan-
tation. H.D. McIntyre, B. Menzies, D.A. Perry-Keene, R. Rigby, i.R.
Hardie, Renal Transplant Unit and Department of Endocrinology,
Princess Alexandra Hospital, Queensland, and Department of Endo-
crinology, Royal Brisbane Hospital, Australia. Serial measurements of
serum and urine markers of bone metabolism and of forearm bone
density by dual photon absorptiometry were performed in 22 renal
transplant recipients at the Princess Alexandra Hospital in 1986.
Patients were randomized to receive (1) cyclosporine alone (CsA, N =
9), (2) cyclosporine for 3 months followed by azathioprine-prednisone(N = 3) or (3) long-term azathioprine-prednisone (N = 9). As no
reduction in bone mineral density (BMD) was noted in the first six
months, groups 2 and 3 were considered together (Aza + Pred group, N
= 12). Overall, mean SD BMD fell from 1.39 0.21 g/cm2 at
transplantation (N = 21), to 1,15 0.24 g/cm2 at 36 months (N = 19),
and 1.19 0.25 g/cm2 at 60 months (N = 14) post-transplant (ANOVA,
P < 0.01). Similar reductions in BMD over 36 months were seen in the
CsA group (17%, P < 0.05) and the Aza + Pred group (19%, P < 0.05).
Small patient numbers made subgroup analysis difficult at 60 months.
The rate of loss of BMD correlated with the dose of methylprednisolone
(MP) received for acute rejection episodes (r = 0.68, P < 0.01) and the
total (MP + oral) prednisolone dose (r = 0.64, P < 0.05). No significant
correlations were observed between the rate of loss of BMD and serum
alkaline phosphatase or urinary hydroxyproline/creatinine or calcium/
creatinine ratios determined shortly after or at 12 months after trans-
plantation. Serum alkaline phosphatase fell post-transplant in patients
treated with Aza + Pred, but not in the CsA group. These results
demonstrate significant loss of forearm bone mineral with long-term
follow-up after renal transplantation, and suggest that patients treated
with cyclosporine without maintenance prednisolone also risk osteope-
nia.
Hypercalcemia and hyperparathyroidism following renal transplanta-
tion. C.M. Hawley, H.D. Mcintyre, R. Grudenich, B. Menzles, E.
Maddens, I. Hardie, G. Briggs, R. Rigby, J. Petrie, M. Suranyi, L.
Hartley, Renal Transplant Unit, Department of Endocrinology, De-
partment of Surgery, Princess Alexandra Hospital, Woolloongabba,
Australia. We performed a retrospective study of all patients with
functioning renal allografts attending our renal transplant clinic, to
evaluate the incidence and natural history of, and factors responsible
for hypercalcaemia, as well as the effect of hypercalcemia on allograft
function and bone status. In the 166 patients with first allografts
followed for a period from 1 to 19 years, we found that the incidence of
hypercalcemia (Ca, Corr > 2.7 mmol/liter) peaked at 32% at 8
months post-transplantation and decreased progressively from that time
reaching approximately 10% at 10 years. There was a linear fall in the
mean plasma calcium concentration with increasing time post-trans-
plant (r = 0.86, P < 0.01). Hypercalcemia was not associated with
impairment of allograft function, and the type of immunosuppressive
therapy received did not appear to influence the incidence of hypercal-
cemia. In hypercalcemic patients there was a significant correlation
between ionized calcium and parathyroid hormone (PTH) (r = 0.55, P
<0.05), ionized calcium and osteocalcin (r = 0.61, P <0.01), PTH and
osteocalcin (r = 0.71, P < 0.01), alkaline phosphatase (ALP) and PTH(r = 0.55, P<0.05), and ALP and osteocalcin (r = 0.51, P <0.05). The
hypercalcemic patients are being further evaluated with detailed symp-
tom analysis, assessment of fracture prevalence, bone densitometry,
measurement of total body calcium, quantification of vascular calcifi-
cation, and bone histomorphometry.
Parathyroidectomy (PTE) ÷ graft dysfunction in renal transplant (TP)
recipients. M.G. Suranyi, C. Hawley, R. Rigby, L. Hartley, J. Petrie, J,
Burke, I. Hardie, Renal Unit and Department of Surgery, Princess
Alexandra Hospital, Brisbane, Australia. Subtotal-PTE post-TP was
reviewed, and 13 cases (1.5—79 months post-TP) found at PAH in the
last 3 years. The indications were hypercalcemia, bone pain and active
hyperparathyroidism. Although renal function was stable despite
t [Ca', prior to PTE, 5/13 had episodes of renal impairment immedi-
ately post-PTE. All patients received oral Vit D, IV or oral Ca and Mg
if required, post-PTE. Of the 5/13 patients with acute renal impairment
after PTE, post-op hypercalcemia occurred in 4/5. In the 1/5 patients
with acute renal impairment after PTE, who was non-hypercalcemic,
only minor serum creatinine (Creat) rise was found, which returned to
baseline with no specific therapy. In the 4/5 hypercalcemic patients
acute rejection was diagnosed clinically, and steroid anti-rejection
therapy was administered in 3 with a beneficial response. Only one had
a renal TP biopsy, which confirmed acute cellular rejection. The fourth
patient received only an increase in the maintenance oral steroid dose
and renal dysfunction and hypercalcemia persisted. In each case with
hypercalcemia and graft dysfunction, the Creat level was found to
closely parallel the post-PTE [Ca], whereas there was no detectable
relationship between [Ca] and Creat prior to PTE. Vit D, PTH and [Ca]
may significantly effect both kidney function and the recipient immune
system. The Creat post-PTE correlated with CCa levels post-PTE,
suggesting that C [Ca] should be avoided in the post-PTE period in TP
recipients. PTE alters Ca, PTH and Vit D levels, all important to
immune cells, or may interfere with the effect of immunosuppressive
drugs.
In vivo effect of losartan (DuP 753) on AT1 angiotensin II receptors
(Ang II) in rat kidney and adrenal. J. Zhuo, P.J. Harris, and F.A.O.
Mendelsohn, Departments of Physiology and Medicine, University of
Melbourne, Austin Hospital, Heidelberg, Victoria, Australia. Our
objective was to investigate in vivo effect of AT1 receptor antagonist,
losartan, on Ang II receptor binding in rat kidney and adrenal by in vitro
autoradiography. Rats (N = 4 each group) were injected with saline or
losartan (1, 3, 10 mg/kg, BW) via the tail vein, killed by decapitation,
and the kidneys and adrenals removed at 1 hour, 2 hours, 8 hours, and
24 hours after injection. Cryostat sections of tissues were incubated in
phosphate buffer containing '251-[Sar', 11e8] Ang II with (non-specific
binding) or without (total binding) unlabeled Ang II. The slides were
exposed to X-ray film and the autoradiographs were analyzed by
computerized densitometry. In the kidney, losartan caused dose- and
time-dependent inhibition of the AT1 binding at glomeruli, proximal
convoluted tubules, and the inner stripe of the outer medulla. The 1
mg/kg dose resulted in 50% inhibition and the 10 mg/kg dose produced
90% inhibition (P < 0.001). These effects peaked at 1 hour, and
persisted for 24 hours. In the adrenal, losartan caused 60% and 40%
inhibition of the AT1 binding at 1 hour (P < 0.001), and the inhibition
fell to 30% and 18% at 24 hours in the cortex and medulla, respectively.
These results indicate that losartan and/or its active metabolite, EXP
3174, selectively block AT1 Ang II receptors in the kidney and adrenal
and may provide a new therapeutic agent in treating renal disorders
associated with activation of intrarenal renin-angiotensin system.
Effects of insulin-like growth factor-I in rats with acute renal failure.
A.A. Martin, C.G. Gillespie, S.J. Hazel, and L.C. Read, Child Health
Research Institute, North Adelaide, South Australia, Australia. Insu-
lin-like growth factor-I (IGF-I) may be therapeutically beneficial in the
treatment of acute renal failure by increasing renal blood flow, glomer-
ular ultrafiltration coefficient and glomerular filtration rate (GFR),
stimulating regeneration of renal tubule cells in acute tubular necrosis
and ameliorating the catabolic state. We examined the efficacy of IGF-I
in improving GFR and enhancing growth in rats with prerenal ARF.
Acute renal failure was produced in male rats, 250 g body weight, by
clamping both renal arteries for 45 minutes. IGF-I, or its variants
des(1—3)IGF-I or LR3-IGF-I, all at dose rate 2 mg/kg/day, were admin-
istered for 7 days via s.c. osmotic pumps. Vehicle alone was adminis-
tered s.c. to the control group. 51CR-EDTA was infused by osmotic
pump i.p. to allow daily calculation of GFR from serum and urine
samples. Rats were held in metabolic cages for daily measurements of
body weight, food and water intake, and 24 hour urine output. GFR was
decreased by 60 to 70% after renal ischemia and was unaffected by IGF
peptide treatment. GFR returned to normal levels on day 7 of treatment
in all four groups of rats. Daily urine output tended to be lower in all
three peptide-treated groups than in the control group, while water
intakes were similar between groups; fluid retention averaged 13 0.7
ml/day (IGF-I), 13 1.1 mI/day [des(l—3)IGF-I] and 14 1.1 mI/day
(LR3-IGF-I), significantly above that in controls (10.3 0.6 ml/day; P
<0.05). Body weight gain over the 7 days was increased in all 3 peptide
groups (averaging 4.6 0.6 g/day (IGF-I), 4.6 0.7 g/day [des(l—
Abstracts 1049
3)IGF-II, 5.1 0.6 g/day (LR3-IGF-I) vs. 1.9 0.6 g/day in controls; P
<0.05), while food intake was similar between groups. Fluid retention
and body weight gain were significantly correlated (R2 = 0.62, P <
0.001). IGF-I and its variants were ineffective in improving GFR in
acute renal failure while causing significantly increased fluid retention
and a related body weight gain. No increased potency of the IGF
variants over the native IGF-I molecule was observed. This study was
supported by the Australian Kidney Foundation.
Evidence for activation of tubuloglomerular feedback (TGF) after
nephrectomy (Nx) in humans. CA. Pollock and M.J. Field, Department
of Medicine, University of Sydney, Concord Hospital, NSW, Australia.
Data from our previous micropuncture experiments in rat models of
renal ablation have demonstrated an increase in TGF activity. This may
have important clinical implications, since manipulations which impair
the TGF response may theoretically result in the long-term deteriora-
tion of renal function by promoting hyperfiltration in individual neph-
rons. We therefore devised a means for determining the role of TGF in
GFR regulation following Nx in normal humans. Six normal subjects
(32—62 years) underwent assessment of GFR (measured as creatinine
clearance) prior, and 4 to 6 weeks subsequent to Nx, performed for the
purpose of living related transplantation. The contribution of TGF to
the regulation of GFR both before and after Nx was assessed by
determining the baseline steady state GFR, and then the GFR with the
effect of TGF activity removed. This was achieved by the administra-
tion of a I mg dose of bumetanide (with quantitative replacement of salt
and water losses), which blocks the afferent arm of the feedback
response. The extent to which GFR rose after bumetanide was taken as
a measure of underlying TGF activation, and this parameter was
compared in the subjects in their pre- and post-Nx state. Baseline GFR
prior to Nx was 115 7 mI/mm, which increased by 9.5 2.5% to 126
9 mI/mm following blockade of TGF. Four to six weeks following Nx
the baseline GFR was 83 8 mI/mm, that is, 72% of the 2 kidney GFR.
After administration of bumetanide, the GFR increased by 15.6 3.1%
to 96 9 mI/mm, a significantly greater fractional rise than that
demonstrated prior to nephrectomy (P < 0.025). These results indicate
an increase in tonic TGF activity in the uninephrectomized state,
compared with that demonstrated prior to Nx. Overall, these results
suggest that the hyperfiltration response following unilateral Nx is
limited by an appropriately activated TGF system. It follows that
clinical maneuvers which blunt TGF, such as loop diuretic therapy and
high protein feeding, may cause long-term deterioration in renal func-
tion as a pathological consequence of an excessively high filtration rate
in the remaining nephrons.
Skeletal muscle metabolism in uremic rats. C.H. Thompson, G.J.
Kemp, Y. Green, G.K. Radda, andJ.G.G. Ledingham, MRCBiochem-
ical and Clinical Magnetic Resonance Unit, John Radcliffe Hospital,
Oxford, United Kingdom. The etiology of uremic myopathy is poorly
understood. Clinical studies suggest impaired oxidative and anaerobic
metabolism. Cation transport is abnormal with decreased NaJK ATPase
activity and elevated intracellular sodium. The effect of uremia on
skeletal muscle metabolism of the rat was examined using 31P magnetic
resonance spectroscopy. Three weeks following either a 5/6 nephrec-
tomy or a sham operation (N = 5 in each group), Wistar rats were
placed in a 7 T magnet and the sciatic nerve stimulated at 2 Hz for 10
minutes. Analysis of spectra taken at rest, during exercise and recovery
allowed calculation of intracellular pH and the relative concentrations
of phosphocreatine (Per), inorganic phosphate (Pi) and ATP. [ADP]
(zmol/kg wet weight) was calculated from the creatine kinase equilib-
rium.
Plasma
mmol/liter
Muscle
Rest Exercise
Recovery
Pcr(t 1/2)
Pi creat Pi/ATP pH [ADP] mm
Uremia
Control
2.4a 0.13a
2.1 0.04
0.43'
0.60
6.96 70
7.01 53
0.86
0.68
a P < 0.05; unpaired t-test
There was a significant reduction in the resting intracellular Pi despite
an elevation in extracellular Pi, probably due to a reduction in the
activity of the membrane Na/Pi cotransporter on account of a reduced
sodium gradient. Despite anemia and uremia, there were no significant
metabolic abnormalities accompanying this substantial reduction of
GFR. In particular, the similar changes during exercise and recovery in
controls and in these uremic animals imply that at this level of renal
impairment there is no mitochondrial dysfunction.
'3C NMR studies of proximal tubular glycine metabolism. G.J. Cowin,
D.A. Willgoss, PA. Stewart-Richardson, Z.H. Endre, University of
Queensland, Department of Medicine, Royal Brisbane Hospital, Her-
ston, Australia. Glycine protects proximal renal tubules from hypoxic
injury, however the mechanism of protection is unknown (1). To follow
tubular metabolism, proximal tubules were isolated from rat kidney
cortex, purified on a Percoll gradient and incubated with 5 mM [2-'3C]
glycine under various conditions. High resolution '3C NMR studies of
PCA extracts of the tubules were obtained at 7.0 and 11.7 T. The results
were correlated with measurements of LDH release to assess tubular
integrity. Rapid conversion of glycine into serine was observed forming
[2-13C], [3-'3CJ and [2,3-'3C} senne via both major metabolic pathways,
viz serine hydroxymethyltransferase (SHMT) and the glycine cleavage
complex (GC). Relative concentrations of [2l3C]glycine and unlabelled
glycine were determined from the ratio of single to double labeled
serine. This technique enables the contribution of de novo glycine
synthesis to be assessed. Reduced single labeled serine was observed
when unlabeled glycine was removed from the preparation steps so that
de novo synthesis became the only source of unlabeled glycine. De
novo formation of glycine was stimulated by addition of unlabelled
serine (reversal of SHMT) and by reoxygenation after hypoxia, sug-
gesting proteolysis and/or peptide cleavage. Inhibition of GC by cyste-
amine resulted in the formation of only [2-'3C] serine. Hypoxia also
resulted only in [2)3C]serine formation, indicating complete GC inhi-
bition with incomplete SHMT inhibition. These preliminary results
support the suggestion [1] that protection by glycine protection of
proximal tubules occurs with little or no metabolism of glycine itself. In
addition, the demonstration that proteolysis is occurring during reoxy-
genation despite the presence of glycine suggests that, at least during
this phase of injury, continuing protection by glycine is not by inhibition
of proteolysis. (1) WEINBERG JM, DAVIS JA, ABARZUA M, RAJAN T: J
Clin Invest 80:1446—1454, 1987
Immunohistochemical localization of chromogranin to glomerular pen-
polar cells of newborn sheep. D. Alcorn, J. McCausland, and G.B.
Ryan, Department of Anatomy, University of Melbourne, Parkville,
Victoria, Australia. Glomerular peripolar cells (PPCs) form a cuff
around the origin of the tuft at the junction between parietal and visceral
podocytic epithelium. One surface of PPCs is attached to Bowman's
capsular basement membrane, the other is directly exposed to the
urinary space. PPCs have been described in a wide range of species;
they are most obvious in newborn lamb kidney. Several proteins
(including albumin, neuron specific enolase, transthyretin) have been
immunohistochemically localized to PPCs of newborn lamb kidney,
suggesting that PPCs may be resorbing proteins from Bowman's space.
However, in newborn lamb kidney, PPC cytoplasm appears highly
synthetic with multiple secretory granules and evidence of regulative
exocytosis into the urinary space. The aim of the present study was to
examine PPCs for the presence of chromogranin, a secretory protein
common to a variety of cells secreting peptides by the regulated
pathway. Kidney tissue from newborn lamb kidney was fixed in Bouin's
fluid and processed through to paraffin sections. Sections were immu-
nostained with monoclonal mouse anti-human chromogranin A antise-
rum (Dako) at a range of concentrations using a modified peroxidase-
anti-peroxidase technique. Chromogranin was specifically localized to
PPCs. Glomeruli, tubules, and blood vessels showed no staining. The
immunohistochemical localization of chromogranin to PPCs of the
newborn lamb kidney provides new evidence for their role as a
regulative secretory cell. The functions of the secretory product(s) of
PPCs await clarification.
Glomerular charge selectivity: The differential processing of dextran
sulfate and DEAE-dextran. W.D. Comper, M. Tay, 1'. Adal, E.F.
Glasgow, and L. Pratt, Biochemistry and Anatomy Departments,
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Monash University, Clayton, Victoria, Australia. We have previously
established (Zamparo and Comper: Biophys Chem 38:167, 1990) that
the Deen-Brenner biophysical model for glomerular charge selectivity
cannot hold. The aim of this study was to examine the processes that
give rise to the differential fractional clearance of dextran sulfate and
DEAE dextran. Studies have been performed with the isolated perfused
rat kidneys which exhibit nearly normal charge selectivity as found in
vivo. The sensitivity of charge selectivity to cycloheximide (Tay et al:
AJP 260:F549, 1991), electron microscopical analysis, autoradiograph-
ical analysis, post-perfusion glomeruli concentration levels of the
dextran transport probes, the kinetics of glomerular turnover of the
various dextran transport probes and their binding to isolated glomer-
ular preparations indicate that the [3H]dextran sulfate but not [3HIdex-
tran, is actively endocytosed by endothelial cells (mesangial cells may
also participate) and is disgorged back into the blood capillary space in
a matter of minutes. This bypass route can account for the retarded
movement of the glomerular transport of dextran sulfate compared to
dextran. In the case of the facilitated transport of [3H]DEAE it appears
that this occurs, not through a cell-mediated process, but by it binding
to the glomerular basement membrane and other glomerular compo-
nents and altering the size selectivity of the membrane.
lschemia lowers kidney osmoprotectant levels. P. Sizeland, S. Cham-
bers, M. Lever, L. Bason, R. Robson, Departments of Nephrology,
Infectious Diseases and Biochemistry, Christchurch Hospital,
Christchurch, New Zealand. This study was carried out to investigate
the effect of an acute ischemic injury on the renal osmoprotectant
system. NZW rats were used, with the vascular pedicle of one kidney
being ligated for 60 minutes. Inner medullary samples of both kidneys
were then analyzed for the osmoprotectants glycine betaine(GB),
myoinositol(MI), sorbitol(S) and glycerophosphocholine (GPC). Con-
centrations (mmol/kg tissue) are shown in the table (mean SEM, N = 9):
GB MI GPC S
Ischemic 4.2 (0.7)a 3.7 (0.4)a 6.4 (2.0)a 0.7 (0.2)
Non-ischemic 7.7 (0.3) 5.7 (0.9) 9.4 (1.9) 0.8 (0.1)
a P < 0.01, vs. non-ischaemic kidney
Ischemia significantly decreased the inner medullary concentrations of
GB, MI, and S compared with non-ischemic controls. Perturbation of
the osmoprotectant system may be important in the etiology of acute
tubular necrosis, and the polyuria which characterizes the recovery
from this.
Vasoactive intestinal peptide (VIP) inhibits sodium uptake in rat
primary proximal tubular cell culture. M.A. Lonergan, S. Aglibut, and
M.J. Field, Department of Medicine, University of Sydney, Concord
Hospital, N.S. W., Australia. VIP has been proposed to play a role in
the regulation of renal sodium (Na) excretion. It has recently been
demonstrated to be present in peripolar cells, where it is ideally placed
to modify renal tubular transport. We therefore examined the effect of
VIP on Na uptake by rat proximal tubular epithelium. Primary cultures
of proximal tubular cells from normal Sprague-Dawley rats were
studied at confluence. After dispersion in dispase, cells were washed
and incubated in low sodium buffer, at pH 7.4 for thirty minutes.
Subsequently 4 groups were studied, characterized by the addition of
ouabain (100 /LM) alone as control, ouabain + VIP (1 sM), ouabain +
amiloride (100 sM), and ouabain + amiloride + VIP. Following
incubation for 15 minutes, aliquots were taken for protein estimation
and cell counting. Na22 uptake was measured in each group at 1, 3 and
30 minutes by taking 20 M1 of cell suspension and adding 70 j.d of high
sodium uptake buffer (Na 120) containing Na22 at 1 Ci per sample. The
reaction was stopped at each time point by the addition of I ml of ice
cold solution containing 149 mrvi LiCI, 0.5 msi Tris and 0.5 msi Hepes.
250 l of the final solution containing cells was collected in a cell
harvester onto filter paper and assayed for radioactivity in a beta
counter. Results are expressed as cpmlmg protein and normalised to the
mean of the sodium uptake in the control group at one minute in each
study. At one minute, Na uptake in the presence of VIP was 66.2
8.1% (SEM, N = 6) of the ouabain control. With amiloride alone, it was
44.6 1.1% and with amiloride + VIP, it was 64.3 8.9%. All
experimental groups were significantly less than control (P < 0.05) but
were not significantly different from each other. We conclude that VIP
inhibits Na22 uptake in rat proximal tubular cells. The data are consis-
tent with a mechanism of inhibition involving decreased activity of the
Na-H exchanger in the apical cell membrane.
Anionic charge concentration of rat kidney glomeruli and glomerular
basement membrane. A.S.N. Lee, M. Tay, and W.D. Comper, Bio-
chemistry Department, Monash University, Clayton, Victoria, Austra-
lia. Estimates of levels of glomerular and glomerular basement mem-
brane anion charge should serve as a useful quantitative markers for the
integrity of the tissues in health and disease. We have developed a
simple, rapid technique to measure this charge through the use of an
exchange technique with radioisotopes 22Na and 35Cl at low ionic
strengths in phosphate buffer. By this technique, normal glomeruli
isolated from rat, have a measured charge concentration of 17.4 3.7
pequiv. per glomerulus (N = 20). Perfused rat kidneys that lose
approximately half of their glomerular [35S]heparin sulfate content (due
to oxygen radical damage) also exhibited a lower anion charge of 7.5
1.6 pequiv. per glomerulus (N = 5). Glomerular basement membranes
prepared from rat glomeruli by simply a sonication-centrifugation
procedure had a charge concentration of 9.0 1.0 mequiv. L1 (N = 4)
whereas membranes prepared by sonication, DNase and detergent
treatment had a charge concentration of 10.8 2.9 mequiv. L' (N =
4). These values are in good agreement with those obtained by others
using titration techniques (Bray and Robinson: Kidney mt 25:527,
1984). We conclude that the exchange technique will provide a useful
routine method by which glomerular and glomerular basement mem-
brane net anion charge can be measured.
Does phosphate loading directly stimulate the parathyroids? M. Co-
chran, B. Dilena, Department of Medicine and Department of Clinical
Biochemistry, Flinders Medical Centre, SA, Australia. It is widely
accepted that the enhanced renal excretion of phosphate that follows
parathyroid stimulation is secondary to changes in plasma calcium
and/or 1 ,25(OH)D2, rather than phosphate itself. Given that PTH is
such a powerful modulator of plasma phosphate, and that there is no
other significant control system, it is surprising that phosphate has no
direct effect at all. To test this, in 5 normal subjects, we administered
Calcium Sandoz I g tds taken with meals, for six days. On the last three
days, the subjects took, in addition, Phosphate Sandoz I g tds two
hours after the calcium supplement. On the first day of the phosphate
supplementation, the subjects omitted breakfast but took the calcium
dose. Blood was sampled before and 60 minutes after the phosphate
dose, which was taken on schedule. The sample was analyzed for total
and ionized calcium, phosphate, intact PTH, and l,25(OH)2D. The
sampling was repeated one hour after the phosphate dose on the sixth
day. Results showed that total and ionised calcium were not signifi-
cantly altered during the study. Phosphate increased in all cases after
the first dose but decreased in two subjects with chronic administration.
The l,25(OH)2D showed no significant change. The PTH increased
within the normal range in all cases following the acute phosphate dose,
and in three cases after chronic administration, but decreased in the two
subjects in whom the plasma phosphate fell. There was a highly
significant relation between these two parameters (P = 0.01). The data
support the idea that an acute phosphate load, and the associated
elevation of the plasma level, can directly promote a parathyroid
response.
Glomerular proteinuria: The involvement of glomerular cells and
heparin sulfate. Y. Adal, W.D. Comper, E.F. Glasgow, and M. Tay,
Biochemistry and Anatomy Departments, Monash University, Clayton,
Victoria, Australia. Two distinct forms of proteinuria have been iden-
tified in an isolated perfused rat kidney (IPK) system. The first form is
the perfusion time-dependent proteinuria that occurs in IPK which is
accompanied by a release of glomerular heparin sulfate into the
perfusate (Vassiliou et a!, 1990) and a decrease in the total glomerular
anion charge concentration. (Note that biophysical studies have dem-
onstrated that while albumin is negatively charged, Z =
—19) it would
not be influenced by a direct charge effect (Coulombic repulsion)
exerted by the GBM heparmn sulfate (Zamparo and Comper, 1990)). A
second, higher level of proteinuria can be induced by the presence of
cycloheximide in the perfusate. This proteinuria is accompanied by no
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change in the size selectivity nor glomerular anion charge concentration
which would indicate that heparin sulfate charge is not involved in this
particular type of albumin processing. Further, normal perfused kid-
neys accumulate high resident levels of glomerular [3H] albumin during
the perfusion. This glomerular albumin accumulation is markedly
reduced when the perfusion is performed in cycloheximide. Isolated
glomeruli from rat kidneys are also able to bind significant quantities of
[3H] albumin in vitro. Electron microscopical studies with gold-albumin
have demonstrated the presence of vesicles containing albumin in
endothelial cells after a two minute perfusion period. The results so far
would be consistent with the hypothesis that some albumin is processed
by glomerular cells through binding and an active uptake and exocytosis
mechanism. VAssILIou, P, TAY M and COMPER WD: Biochem mt
19:1241, 1989; Zamparo, Q, and Comper WD: Biophys Chem 38:167,
1990
The effect of interleukin 1 on glomerular sclerosis. H. Y. Wang, Z.H.
Zhao, Nephrology Center, Beijing Medical University, Being, China.
Interleukin 1 (IL-l) is a pleiotropic factor, eliciting a broad set of
immunologic and inflammatory events. We have previously shown that
mesangial cells (MSc) produced IL-l like factors has the effect of
stimulating MSc proliferation. To evaluate the role of IL-I on glomer-
ulosclerosis (GS), we observed IL-l and TGF-/3 mRNA expression
(Northern blot) during the development of GS and cellular matrix
accumulation (collagen IV, CoIV, laminin, LN, fibronetin, FN, by 35S
incorporation and collagen assay) in ATS model. Also, the effect of
rIL-l on stimulating cultured MSc expressing TGF-/3 mRNA and
producing cellular matrix was studied. Our results showed: (I) During
the development of GS in ATS rat, the expression of IL-I and TGF-/3
increased (2- to 3-fold more than normal control) at day 7 combining
with the increasing of CoIV (29.39 2.40 vs. 2.64 0.89), LN (20.46
1.53 vs. 2.93 0.18), and FN, (17.55 1.05 vs. 4.91 0.77), but not
at day when GS was identified morphologically and matrix accumula-
tion was continued. (2) rIL-l/3 stimulated TGF-/3 mRNA gene expres-
sion and promoted 35S incorporation (1586 282 vs. 700 109),
collagen synthesis (6.81 0.70 vs. 4.20 0.68) in subcultured MSc.
These explorations of both experiment animal and cellular studies
indicate that IL-i plays an important role in the development of GS.
Involvement of activated interstitial leukocytes in disruption of Bow-
man's capsule and crescent progression in experimental anti-GBM dis-
ease. H. Y. Lan, D.J. Nikolic-Paterson, R.C. Atkins, Department of
Nephrology, Monash Medical Centre, Clayton, Victoria, Australia. We
have investigated whether interstitial leukocytes could induce glomer-
ular damage by causing disruption of Bowman's capsule (BC) in
experimental anti-GBM disease. Disease was induced in inbred
Sprague-Dawley rats by administration of rabbit anti-GBM serum 5
days after immunization with normal rabbit IgG, with groups of 4
animals sacrificed at days 3, 7, 14, 21, and 28. Leukocytic infiltration
was analyzed by monoclonal antibody (Mab) labeling of cryostat
sections. Periglomerular macrophage and T cell infiltration was evident
at day 3. Activated (IL-2R) mononuclear cells (MNC) were first seen
in the hilar area at day 7, and were then found in focal accumulations in
the periglomet-ular area from day 14. Disruption of BC was first evident
at day 14; all animals at days 14 to 28 exhibited BC rupture, while 11/12
animals displayed crescent formation (25—74%). Analysis of 200 glomer-
uli per animal on PAS-stained paraffin sections found that disruption of
BC occurred in both the presence (48—74%) and absence (26—52%) of
crescent formation. However, disruption of BC was invariably associ-
ated with sites of focal periglomerular MNC infiltration, whereas BC
remained intact where periglomerular infiltration was mild. Mab label-
ing revealed that focal MNC infiltrates associated with BC rupture
contained IL-2R cells and macrophages. Fibrous organization of
cellular crescents and the presence of IL-2R cells within crescents
occurred only when BC was ruptured. In summary, this study has
demonstrated that BC disruption occurred in both the absence and
presence of cellular crescents, and that disruption of BC only occurred
in tight association with focal periglomerular infiltrates of activated
MNC. In glomeruli with crescent formation, disruption of BC appeared
to be an essential step in progressive fibrosis of cellular crescents.
Disruption of BC by interstitial leucocytes, via a DTH-type reaction,
may be an important mechanism of glomerular damage.
Lipid peroxidation (LP) in passive heymann's nephritis (PHN). T.J.
Neale, P.P. Ojha, J. Witzum, H. Pocewski, M. Exner, D. Kerjaschki,
Department of Medicine, Wellington School of Medicine; Institute of
Pathology, Vienna, Austria, and Department of Medicine, UCSD, La
Jolla, California, USA. Our previous studies have shown that the rat
glomerular epithelial cell (GEC) expresses the NADPH-oxido-reduc-
tase enzyme component, cytochrome b558 and that this is up-regulated
after GEC activation by anti-FxIA antibody in PHN. Cytochrome
functional activity, assessed as H202 production, was specifically
histochemically revealed ultrastructurally by cerium capture within
proteinuric glomeruli. The current study sought to determine if LP
occurred in PHN as a consequence of this local release of reactive
oxygen species (ROS). The LP markers malondialdehyde (MDA) and
4-hydroxynonenal (4-HNE) were specifically identified within the gb-
meruli of rats with proteinuric PHN using monoclonal antibody IF and
immunoblotting. Immunogold EM localized MDA to GEC structures
(particularly cytoplasmic vesicles and cell membranes), the glomerular
basement membrane (GBM), the subepithelial space, and to areas in
relationship to immune deposits. Autoradiography of immunoprecipi-
tates of tritium-labeled GBM from proteinuric rats using antisera
against extracellular matrix proteins showed that type IV collagen was
a ligand for MDA. These findings are consistent with the hypothesis
that ROS-induced glomerular injury in PHN is mediated by LP, and the
close temporal correlation with the onset of proteinuria suggests a
causal role for LP in glomerular permselectivity alteration.
Total numbers of glomeruli and individual glomerular cell types in the
normal rat kidney. J.F. Bertram, M.C. Soosaipillai, S.D. Ricardo, and
G.B. Ryan, Department of Anatomy, University of Melbourne,
Parkville, Victoria, Australia. Various renal disorders are associated
with changes in glomerular and glomerular cell number. In the present
study, new unbiased stereological counting methods (Gundersen et al:
APMIS 96:857—881, 1988) were used to estimate total numbers of
glomeruli and individual glomerular cell types in normal rats. Unlike
traditional stereological methods, these new methods do not require
assumptions of glomerular or nuclear shape, size distribution or orien-
tation, and thereby provide unbiased estimates. The kidneys of seven
female Sprague-Dawbey rats weighing 215 16 g (mean SD) were
perfused with 4% paraformaldehyde and 1% glutaraldehyde in phos-
phate buffer and tissue was processed for embedding in either glycol-
methacrylate (light microscopy, LM) or epon/araldite (transmission
electron microscopy, TEM). Total glomerular number was estimated
using a physical disector/fractionator combination at the LM level, the
total number of cells per average glomerulus was estimated using an
optical disector/Cavalieri combination at the LM level, and numbers of
individual cell types were estimated using TEM physical disectors. The
normal rat kidney was found to contain 31,764 3,667 glomeruli. An
average glomerulus contained 674 129 cells, of which 181 53 were
epithelial cells (podocytes), 248 53 were endothelial cells, and 245
45 were mesangial cells. An average renal corpuscle contained 117 27
parietal epithelial cells. These estimates generally agree with those
previously obtained using traditional counting methods such as serial
section reconstruction, maceration, or biased stereological methods.
The efficacy of the present counting methods are remarkable: on
average, following sectioning and staining, less than 6.5 hours was
needed to obtain estimates for a single animal, with coefficients of
variation (standard deviation expressed as a percentage of the mean)
ranging from 10% to 30%. These data provide a baseline for experimen-
tal studies of glomerular disease.
Urinary platelet factor 4 (PF4) and mesangial IgA glomerulonephritis(IgAGN). Koji Taira, Tim Hewitson, and Priscilla Kincaid-Smith,
Department of Nephrology, Royal Melbourne Hospital, Victoria, Aus-
tralia. The aim of this study was to determine if platelets and the
specific platelet release protein PF4 are associated with glomerular
injury in IgAGN. Urine samples from patients with IgAGN were
examined by ELISA to determine the concentration of PF4 ([PF4I; N =
51) and by immunoperoxidase (IP) staining for the presence of urine
sediment platelets (N = 18). Renal biopsy tissue taken within 24 hours
of urine sampling was stained by IP for glomerular platelets (N = 39).
Elevated urinary [PF4] (0.07 ng/ml) was associated with the presence
of active gbomerular crescents (P < 0.005) and fibrin deposition (P <
0.01). [PF4] was higher in patients with crescents (P < 0.05), and
1052 Abstracts
glomerular fibrin deposition (P < 0.05) than those without. Likewise,
the presence of glomerular platelets and urine platelets was associated
with glomerular crescent formation (P < 0.02, P < 0.05, respectively),
although there was no such association with fibrin deposition. There
was no relationship between urine [PF4], urine platelets or glomerular
platelets and the presence of either global sclerosis or focal and
segmental hyalinosis and sclerosis. There was a strong correlation
between elevated urine PF4] and the presence of glomerular PF4
staining (P < 0.0001) and urine sediment platelets (P < 0.005). These
results suggest that an assay for urine [PF4] may be a useful prognostic
indicator of severe glomerular injury in patients with IgAGN.
Electron microscopy of glomerular changes in experimental pre-
eclampsia. A. Hennessy, A.F. Phippard, P.D. Kirwan, D.M. Painter,
J.S. Horvath, Department of Renal Medicine and Anatomical Pathol-
ogy, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW,
Australia, Rational management of pre-eclampsia (FE), a syndrome of
hypertension and proteinuria arising de novo in pregnancy and reversed
by delivery, has been confounded by two problems: lack of diagnostic
criteria and uncertain pathogenetic mechanisms. To test the proposition
that placental ischemia causes pre-eclampsia, we have conducted
studies in the chronically-instrumented baboon (Papio hamadryas).
During late pregnancy hypertension and proteinuria are experimentally
induced by reduction in placental perfusion. Renal histology performed
at the time of delivery and at twelve weeks post-partum has demon-
strated the characteristic glomerular lesion of FE by light microscopy
(LM). The aim of the present study was to further characterize by
electron microscopy (EM) the glomerular pathology associated with
this animal model of PE. Open renal cortical wedge biopsy was
performed at the time of delivery. Tissue blocks 1 mm x 1 mm were
immediately fixed in 2.5% glutaraldehyde and processed in a routine
fashion for EM. They were then examined with toluene blue staining for
abnormal glomeruli. These glomeruli were then scanned by transmis-
sion electron microscopy TEM (Phillips). The same animals had con-
tralateral renal biopsies at three months post-partum. EM studies
provided ultrastructural definition of glomerular swelling and capillary
changes identified by LM. Contributing abnormalities were endothelial
cell swelling and disruption with resultant glomerular capillary occlu-
sion. Additional changes were subendothelial fibrin deposits with early
reduplication of the basement membrane as well as mesangial interpo-
sition. Some fibrinoid and dense deposits were seen in the glomerular
basement membranes and mesangial areas. No further pathology indic-
ative of inflammatory change was identified. The post-partum biopsies
had regressed. These sequential EM findings support the proposition
that placental hypoperfusion leads to pre-eclampsia.
A quantitative analysis of renal arteriosclerosis in diabetic nephrop-
athy: Clinicopathological correlations. Ian R. Fraser, Kathy M.
Nicholls, Priscilla S. Kincaid-Smith, Department of Nephrology, Royal
Melbourne Hospital, Melbourne, Victoria, Australia. A computer aided
image-analyzer was used to determine an index of arteriosclerosis in the
renal biopsies of diabetics with nephropathy. All blood vessels judged
to be sectioned end on were measured. The blood vessel wall and total
blood vessel surface area measured, and the two were expressed as a
ratio. The mean ratio for a patient was taken as the index of arterio-
sclerosis (IA). A total of 62 diabetics and 17 controls (15 immediate
transplant biopsies and 2 graft nephrectomies for carcinoma) were
measured by the one blinded observer. A minimum of 15 blood vessels
were measured, with a mean coefficient of variance of 10.7%. Patients
characteristics are listed below.
No. Age Sex (M: F) Creatinine Proteinuria
Diabetic 62 46(20—71) 35:17 0.11 mmol/liter 0.94 g/day
Control 17 42 (26—64) 7:10 —
All diabetics had a mean urinary albumin excretion (UAE) greater than
30 g/min. Forty-two patients had glomerular filtration rate (GFR)
estimated by technetium labeled DTPA nuclear scan. The diabetics had
a significantly greater index of arteriosclerosis (IA) when compared to
controls (0.794 vs. 0.751 P < 0.001). There was a significant correlation
between the IA and estimates of renal function; GFR (r =
—0.38, P <
0.001), creatinine (r = 0.40, P < 0.004). There was no correlation
between IA and the following: systolic or diastolic blood pressure, age
urinary protein excretion, duration of diabetes, type of diabetes, serum
cholesterol and past of present cigarette use. We describe a method of
quantifying arteriosclerosis in renal biopsies. There is a significant
correlation between the severity of arteriosclerosis and renal function,
suggesting extraglomerular arteriolar disease may be an important
determinant of renal function in diabetes.
Sub-thrombotic dose of thrombin produces thrombi in the glomeruli of
cyclosporine (CsA)-treated rabbits. P. Faraco. T. Hewitson, P. Kincaid-
Smith, Department of Nephrology, Royal Melbourne Hospital, Victo-
ria, Australia. CsA has been associated with glomerular thrombosis and
the mechanisms involved are not known. Previously, we reported that
infusion of sub-thrombotic doses of endotoxin in CsA-treated rabbits
produces massive deposition of fibrin in the glomeruli. To investigate if
inflammatory mediators stimulated by endotoxin are important factors
involved in the model above, we infused CsA-treated rabbits with
sub-thrombotic doses of endotoxin-free thrombin. Twenty NZW rab-
bits were divided in four groups. The animals received CsA (25
mg/kg/day) or diluent for 10 days and were infused with thrombin (1
HIH unit/kg/mm) or saline on day 11. After infusion they were
sacrificed, kidneys removed and processed for light and electron
microscopy. Control group received CsA diluent and saline. CsA group
received CsA for 10 days and saline. Thrombin group received diluent
for 10 days and thrombin. CsA + thrombin group received CsA and
thrombin. No fibrin deposition was found in control and CsA groups.
We found 3.7% glomeruli with fibrin in the thrombin group and 76.6%
glomeruli with fibrin in CsA + thrombin group (P < 0.001). No
glomerular thrombi were observed in the thrombin group but in group
CsA + thrombin 47.3% glomeruli contained thrombi. These results are
very similar to those observed for CsA-treated rabbits infused with
endotoxin. We concluded that the deposition of fibrin in the glomeruli of
rabbits treated with CsA and infused with endotoxin is not due to the
interaction between CsA and inflammatory mediators as it has been
hypothesized before.
Lysosomal iron (FE), reactive oxygen species (ROS) and puromycin
nephrosis (PAN). B.J. Nankivell, C. Tay, G. Mill, R.A. Boadle, D.C.H.
Harris, Department Renal Medicine and EM Unit, Westmead Hospital,
NSW, Australia. ROS have been implicated in the pathophysiology of
puromycin nephrosis. As Fe catalyses ROS production and has been
found in other models of renal disease, this study examined for the
presence of Fe and its possible relationship to ROS and proteinuna in
male Wistar rats given PAN (10 mg/100 g body wt i.v.) and saline
controls. At the time of peak proteinuria (day 12) and recovery (day 33),
Fe was examined by atomic absorption spectroscopy and EM energy
dispersive analysis, transferrin (TF) by radial immunodiffusion and
ROS by malondialdehyde (MDA).
Pea
(N=
k
14)
Recovery(N=19) P<
Proteinuria mg/24 hrs 277.4 19,2b 15.1 0.9 0.001
Urine Fe jsg/24 hrs 22.4 2.1" 2.2 0.3a 0.001
Urine TF mg/24 hrs 34.9 3.4" 0.44 0.11 0.001
Plasma MDA nmol/liter 23.9 5.1" 9.8 0.7 0.01
Tissue MDA nmol/mg protein
Lysosomal Fe wt %"
0.55
331.8
0.04
65.1"
0.72 0.09
120.5 33.6
NS
0.01
a p < 0.05, b P < 0.01 vs. controls, C control = 26.5 13.7
The numbers of Fe containing lysosomes/tubule correlated with urinary
Fe (r = 0.91, P < 0.001) and also with urine TF and proteinuria. In
conclusion, iron accumulates in proximal tubule lysosomes during the
proteinuric phase of PAN nephrosis, probably gains access to the cell
across the brush border membrane and appears to turn over rapidly.
Iron (FE) depletion and reactive oxygen species (ROS) in the remnant
kidney. B.J. Nankivell, R.A. Boadle, C. Tay, G.K. Mill, D.C.H. Harris,
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Department of Renal Medicine, Westmead Hospital, NSW, Australia.
Fe accumulates in RK proximal tubular lysosomes, and by catalysis of
ROS may be involved in disease progression. To determine the signif-
icance of lysosomal Fe accumulation, the effect of Fe depletion (by
dietary restriction venesection) was examined in 5 groups of partially
nephrectomized (¾) male Wistar rats. Groups 1—3 were pairfed a diet
containing adequate cysteine and methionine containing sulphydryl
(SH) groups, which scavenge ROS and groups 4—5 were pairfed a diet
deficient in SH groups, for 6 months. GFR was assessed by Tc DTPA
clearance, Fe by energy dispersive analysis, and ROS by MDA pro-
duction and glutathione.
GFR
Gp
Diet Fe
mg/kg
mI/mm/kg
body WI.
Proteinuria
mg/24 hrs
Lysosomal Fe
mean wt%
Hb
giliter
1 100 2.45 0.30 40.1 9.4 197.4 70.3 150 6
2 0 2.05 0.43 56.3 18.7 36.3 20.9a 121 a
3 0 + v 2.70 0.34 37.5 10.9 10.9 6.1k 128 9
4 250 2.70 0.30 87.4 15.2 51.0 17.67 157 5
5 0 + v 2.10 0.47 209.2 21.7" 32.7 11.7 123
In Fe replete rats, lysosomal Fe correlated with proteinuria (r = 0.63, P
= 0.014) and MDA production (r = 0.50). In SH-deficient rats, Fe
depletion was associated with increased tissue MDA (0.74 0.05 vs.
0.57 0.06 nmol/mg protein, gp 5 vs. 4, P < 0.05) and reduced total
glutathione (164.5 5.1 vs. 108.7 6.7 jsmol/mg protein, P < 0.05),
and tissue MDA correlated with proteinuria (r = 0.62, P = 0.016). In
summary, in RK Fe depletion reduces lysosomal Fe without protecting
renal function, and exacerbates injury when ROS are not scavenged.
Proximal tubular lysosomal iron (FE) in the remnant kidney (RK). B.J.
Nankivell, R.A. Boadle, D.C.H. Harris, Department of Renal Medi-
cine, Westmead Hospital, NSW, Australia. Fe accumulates in proximal
tubule lysosomes of several models of chronic renal failure. To examine
the significance of proximal tubule lysosomal Fe in RK, a morpholog-
ical study was performed in male Wistar rats after 5/6 nephrectomy (N
= 17) vs. controls (N, N = 8). After in vivo pet-fusion with Karnovsky's
solution, cortical sections were examined by conventional EM for type
and size of lysosomes in proximal tubules and cell damage (scored 0—4)
and energy dispersive analysis for Fe (quantified by the Hall method).
Lysosomes RK N P <
Primary
Secondary %
41.2
29.6
23.5}
47.9} ch2 0 001
Phagolysosomes 29.2 28.6 NS
Number/tubulea 8.42 0.41 11.97 0.42 0.001
Area p.m2a 0.39 0.02 0.34 0.01 0.001
Fe WI % 220.7 65.5 58.8 27.9 0.05
Cell damage scorea 2.94 0.04 0.68 0.03 0.001
a Mean SEM
In RK rats, proteinuria correlated directly with the number of Fe
containing lysosomes/proximal tubule (r = 0.56, P = 0.03) and with
mean lysosomal area (r = 0.66, P < 0.01). Calculated lysosomal volume
increased by 41% in RK. Tubular cell damage correlated directly with
lysosomal Fe content(r = 0.41, P = 0.005). In summary, RK have more
primary lysosomes, and larger digestive secondary lysosomes contain-
ing increased amounts of Fe, abnormalities which are associated with
cell damage and may be induced by proteinuria.
Glomerular volume in non-insulin dependent diabetes mellitus. Ian R.
Fraser, Kathy M. Nicholls, Priscilla S. Kincaid-Smith, Department of
Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Austra-
lia. We quantified the light microscopic changes in a group of patients
with insulin dependent diabetes mellitus (LDDM), (N = 20), and
non-insulin dependent diabetes mellitus (NIDDM), (N = 19), and
compared them to cadaveric donors, matched for age (N = 28). The
renal donors were separated into 2 groups, to match the ages of the
diabetic groups. All diabetics had a mean urinary albumin excretion
(UAE) greater than 30 .tg/min. A quantitative analysis was performed
blindly—on sections stained with periodic acid Schiff's reagent (PAS),
using point counting. The following parameters measured: (I) mean
glomerular volume (MGV), (2) volume fraction of capillary lumina
(VvC), and (3) — volume fraction of PAS positive material (VvP). MGV
for both NIDDM (1.57 M3 vs. 0.88 P < 0.001) and IDDM (1.22 vs.
0.62 P < 0.001) groups were significantly greater than controls on point
counting. There was no difference between NIDDM and IDDM for
either VvC or VvP. MGV was significantly greater in the NIDDM when
compared to the IDDM (P < 0.05). There was a significant correlation
between age and MGV in the control group (r = 0.55, P = 0.003). These
results suggest that the glomerular hypertrophy seen in IDDM also
occurs in NIDDM, and that the nature of the enlargement is the same.
The difference in MGV between the two diabetic groups can be
explained, in part, by the effect of ageing on glomerular volume, as
demonstrated in the control group.
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Mean SEM a P < 0.05 vs. gpl, b P < 0.01 vs. gp4
